



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 495/04, 217/06, A61K 31/435, 31/47		A1	(11) International Publication Number: WO 98/40385 (43) International Publication Date: 17 September 1998 (17.09.98)
(21) International Application Number: PCT/DK98/00083 (22) International Filing Date: 6 March 1998 (06.03.98)		(74) Common Representative: NOVO NORDISK A/S; Corporate Patents, Novo Allé, DK-2880 Bagsværd (DK).	
(30) Priority Data: 0249/97 7 March 1997 (07.03.97) DK 1365/97 27 November 1997 (27.11.97) DK		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIGO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(71) Applicant (for all designated States except US): NOVO NORDISK A/S [DK/DK]; Novo Allé, DK-2880 Bagsværd (DK). (72) Inventors; and (75) Inventors/Applicants (for US only): MADSEN, Peter [DK/DK]; Ulvebjerg 7, DK-2880 Bagsværd (DK). LUND-BECK, Jane, Marie [DK/DK]; Evas Allé 19, DK-2600 Glostrup (DK). WESTERGAARD, Niels [DK/DK]; Tibberup Allé 36A, DK-3500 Værløse (DK). NÆRUM, Lars [DK/DK]; Alrunevej 14, DK-2900 Hellerup (DK). VARMING, Annemarie, Reinhardt [DK/DK]; Fredens Plads 1, DK-2920 Charlottenlund (DK). DEMUTH, Helle [DK/DK]; Fuglemosevej 5, DK-2970 Hørsholm (DK). HEIDE, Morten [DK/DK]; Søllerød Park 12-22, DK-2840 Holte (DK).		Published With international search report.	

(54) Title: 4,5,6,7-TETRAHYDRO-THIENO[3,2-c]PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE

(57) Abstract

4,5,6,7-tetrahydro-thieno[3,2-c]pyridine derivative modulate the activity of molecules with glucose-6-phosphate recognition units, including glucose-6-phosphatases (G-6-Pases) in *in vitro* systems, microorganisms, eukaryotic cells, whole animals and human beings, and are useful in the treatment of diseases related to glucose metabolic pathways.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

4,5,6,7-Tetrahydro-thieno[3,2-c]pyridine Derivatives, their Preparation and UseField of the invention

The present invention relates to 4,5,6,7-tetrahydro-thieno[3,2-c]pyridine derivatives, to methods for their preparation, to compositions comprising the compounds, to the use of these compounds as medicaments and their use in therapy, e.g. to their use for treatment of human and animal disorders. The invention relates to modulation of the activity of molecules with glucose-6-phosphate recognition units, including glucose-6-phosphatases (G-6-Pases) in *in vitro* systems, microorganisms, eukaryotic cells, whole animals and human beings, especially in the treatment of diseases related to glucose metabolic pathways.

Background of the invention

Glucose is the major energy substrate in mammals and regulation of blood glucose levels within a narrow range seems to be of crucial importance to avoid serious physiological complications as seen in diabetes (DeFronzo, Bonadonna, & Ferrannini. 1992). Blood glucose homeostasis is maintained by dietary intake of carbohydrates, the uptake of glucose by peripheral tissues and the brain, and storage or release of glucose from the liver. The liver therefore seems to play a major role in the homeostatic regulation of blood glucose levels. Gluconeogenesis and glycogenolysis are the two metabolic pathways from which glucose can be produced in the liver. These pathways are under tight hormonal control. Insulin resistance and insulin deficiency have a substantial impact on glucose production in the liver (Consoli. 1992; DeFronzo, Bonadonna, & Ferrannini. 1992; Clore, Stillman, Stevens, Blackard, Levy, & Richmond. 1996). Glucose-6-phosphatase (G-6-Pase) catalyses the terminal step in the above mentioned pathways by converting glucose-6-phosphate (G-6-P) to glucose, and is largely situated in the liver, with some expression in the kidney after prolonged fasting. The G-6-Pase is a multicomponent system comprising of the G-6-Pase catalytic enzyme with its active site located at the luminal site of the endoplasmic reticulum (microsomal fraction), a specific transporter T1 which mediates entry of G-6-P into the luminal compartment, and transporter T2 and T3 which mediates export to the cytosol of inorganic phosphate and glucose, respectively (Nordlie, Bode, & Foster. 1993; Sukalski & Nordlie. 1989). It has been shown that the rate of hydrolysis of G-6-P and the hepatic glucose output were increased under diabetic conditions (Lyall, Grant, Scott, & Burchell. 1992; DeFronzo, Bonadonna, & Ferrannini. 1992). The increased activity could mainly be accounted for by increased G-6-Pase catalytic enzyme protein (Argaud, Zhang, Pan, Maitra, Pilkis, &

Lange. 1996; Burchell & Cain. 1985). This makes G-6-Pase enzyme a potential target in control of excess glucose production seen in diabetes.

5 Bibliography

Argaud, D., Zhang, Q., Pan, W., Maitra, S., Pilkis, S.J., & Lange, A. (1996). Regulation of rat liver glucose-6-phosphatase gene expression in different nutritional and hormonal states. *Diabetes*, 45:1563-1571.

Arion, J.M., Lange, A.J., & Walls, H.E. (1980). Microsomal membrane integrity and the interactions of phlorizin with the glucose-6-phosphatase system. *J Biol Chem*, 255:10387-10395.

Burchell, A., & Cain, D.I. (1985). Rat hepatic microsomal glucose-6-phosphatase protein levels are increased in streptozotocin-induced diabetes. *Diabetologia*, 28: (852). 856

Clore, J.N., Stillman, J.S., Stevens, W., Blackard, W.G., Levy, J., & Richmond, V.A. (1996). Chronic hyperinsulinemia suppresses glucose-6-phosphatase mRNA. *Diabetes*, 44 (suppl 1):253A

Consoli, A. (1992). Role of liver in pathophysiology of NIDDM. *Diabetes Care*, 15:430-441.

DeFronzo, R.A., Bonadonna, R.C., & Ferrannini, E. (1992). Pathogenesis of NIDDM: A Balanced overview. *Diabetes Care*, 15:318-368.


Lyall, H., Grant, A., Scott, H.M., & Burchell, A. (1992). Regulation of the hepatic microsomal glucose-6-phosphatase enzyme. *Biochem Soc Trans*, 20, 271S (abstract).

Nordlie, R.C., Bode, A.M., & Foster, J.D. (1993). Recent advances in hepatic glucose 6-phosphatase regulation and function. *Proc Soc Exp Biol Med*, 203:274-285.

Sukalski, K.A., & Nordlie, R.C. (1989). Glucose-6-phosphatase: Two concepts of membrane function relationship. In A. Meister (Ed.), *Advances in Enzymology and related areas of molecular biology*. (pp. 93-117). New York: John Wiley and Sons.

30 Description of the invention

The present invention relates to compounds of the general formula I:



wherein

A together with the double bond of formula I forms a cyclic system selected from the group

5 consisting of benzene, thiophene, furan, pyridine, pyrimidine, pyrazine, pyridazine, pyrrole, indole, pyrazole, imidazole, oxazole, isoxazole or thiazole,

R¹ is C₁₋₆-alkyl, or aryl, optionally substituted with one or more substituents,

R² is C₁₋₆-alkyl, aralkyl, or COR³ optionally substituted with one or more substituents,

10 R³ is C₁₋₆-alkyl, aralkyl, or aryl, optionally substituted with one or more substituents,

R⁴ and R⁵ independently are hydrogen, halogen, perhalomethyl, optionally substituted C₁₋₆-alkyl, hydroxy, optionally substituted C₁₋₆-alkoxy, nitro, cyano, amino, optionally substituted mono- or di-C₁₋₆-alkylamino, acylamino, C₁₋₆-alkoxycarbonyl, carboxy or carbamoyl,

15 n is 0, 1, or 2, and

m is 0, 1, or 2,

or a salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric form.

20 Within its scope the invention includes all isomers of compounds of formula I, some of which are optically active, and also their mixtures including racemic mixture thereof.

The scope of the invention also includes all tautomeric forms of the compounds of formula I.

25 The compounds according to the invention may optionally exist as pharmaceutically acceptable salts including pharmaceutically acceptable acid addition salts, such as hydrochloric, hydrobromic, hydroiodic, phosphoric, sulfuric, acetic, trifluoroacetic, trichloroacetic, oxalic, maleic, pyruvic, malonic, succinic, citric, tartaric, fumaric, mandelic, benzoic, cinnamic, methanesulfonic, ethanesulfonic, picric and the like, and include the pharmaceutically ac-

ceptable salts listed in *Journal of Pharmaceutical Science*, 66, 2 (1977) and incorporated herein by reference; pharmaceutically acceptable metal salts, such as lithium, sodium, potassium, or magnesium salts and the like; or - optionally alkylated - ammonium salts; or amine salts of the compounds of this invention, such as the sodium, potassium, C_{1-6} -5 alkylamine, di (C_{1-6} -alkyl) amine, tri (C_{1-6} -alkyl) amine and the four (4) corresponding omega-hydroxy analogues (e.g. methylamine, ethylamine, propylamine, dimethylamine, diethylamine, dipropylamine, trimethylamine, triethylamine, tripropylamine, di(hydroxyethyl)amine, and the like; Also intended as pharmaceutically acceptable acid addition salts are the hydrates which the present compounds are able to form. The acid addition salts may be obtained as the direct products of compound synthesis. In the alternative, the free base may be dissolved in a suitable solvent containing the appropriate acid, and the salt isolated by evaporating the solvent or otherwise separating the salt and solvent. The compounds of this invention may form solvates with standard low molecular weight solvents using methods known to the skilled artisan.

15

The term " C_{1-6} -alkyl" as used herein, alone or in combination, refers to a straight or branched, saturated or unsaturated hydrocarbon chain. The C_{1-6} -alkyl residues include aliphatic hydrocarbon residues, unsaturated aliphatic hydrocarbon residues, alicyclic hydrocarbon residues. Examples of the aliphatic hydrocarbon residues include saturated aliphatic hydrocarbon residues having 1 to 6 carbon atoms such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec.butyl, tert.butyl, n-pentyl, isopentyl, neopentyl, tert.pentyl, n-hexyl, iso-hexyl. Example of the unsaturated aliphatic hydrocarbon residues includ those having 2 to 6 carbon atoms such as ethenyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-methyl-1-propenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 3-methyl-2-butenyl, 1-25 hexenyl, 3-hexenyl, 2,4-hexadienyl, 5-hexenyl, ethynyl, 1-propionyl, 2-propionyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-pentynyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-hexynyl, 3-hexynyl, 2,4-hexadiynyl, 5-hexynyl. Examples of the alicyclic hydrocarbon residue include saturated alicyclic hydrocarbon residues having 3 to 6 carbon atoms such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl; and C_{5-6} unsaturated alicyclic hydrocarbon residues having 5 to 6 carbon atoms such as 1-cyclopentenyl, 2-cyclopentenyl, 3-cyclopentenyl, 1-cyclohexenyl, 2-cyclohexenyl, 3-cyclohexenyl.

The terms "lower alkyl" and "lower alkoxy" mean C_{1-6} -alkyl and C_{1-6} -alkoxy, respectively.

The term "aryl" as used herein refers to an aryl which can be optionally substituted or a heteroaryl which can be optionally substituted and includes phenyl, biphenyl, indene, fluorene, naphthyl (1-naphthyl, 2-naphthyl), anthracene (1-anthracyl, 2-anthracyl, 3-anthracyl), pyrrolyl (2-pyrrolyl), pyrazolyl (e.g. 3-pyrazolyl, 4-pyrazolyl and 5-pyrazolyl), imidazolyl (1-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl), triazolyl (1,2,3-triazol-1-yl, 1,2,3-triazol-2-yl 1,2,3-triazol-4-yl, 1,2,4-triazol-3-yl), oxazolyl (2-oxazolyl, 4-oxazolyl, 5-oxazolyl), thiazolyl (2-thiazolyl, 4-thiazolyl, 5-thiazolyl), pyridyl (2-pyridyl, 3-pyridyl, 4-pyridyl), pyrimidinyl (2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 6-pyrimidinyl), pyrazinyl, pyridazinyl (3-pyridazinyl, 4-pyridazinyl, 5-pyridazinyl), quinolyl (2-quinolyl, 3-quinolyl, 4-quinolyl, 5-quinolyl, 6-quinolyl, 7-quinolyl, 8-quinolyl), isoquinolyl (1-isoquinolyl, 3-isoquinolyl, 4-isoquinolyl, 5-isoquinolyl, 6-isoquinolyl, 7-isoquinolyl, 8-isoquinolyl), benzo[b]furanyl (2-benzo[b]furanyl, 3-benzo[b]furanyl, 4-benzo[b]furanyl, 5-benzo[b]furanyl, 6-benzo[b]furanyl, 7-benzo[b]furanyl), 2,3-dihydro-benzo[b]furanyl (2-(2,3-dihydro-benzo[b]furanyl), 3-(2,3-dihydro-benzo[b]furanyl), 4-(2,3-dihydro-benzo[b]furanyl), 5-(2,3-dihydro-benzo[b]furanyl), 6-(2,3-dihydro-benzo[b]furanyl), 7-(2,3-dihydro-benzo[b]furanyl), benzo[b]thiophenyl (2-benzo[b]thiophenyl, 3-benzo[b]thiophenyl, 4-benzo[b]thiophenyl, 5-benzo[b]thiophenyl, 6-benzo[b]thiophenyl, 7-benzo[b]thiophenyl), 2,3-dihydro-benzo[b]thiophenyl (2-(2,3-dihydro-benzo[b]thiophenyl), 3-(2,3-dihydro-benzo[b]thiophenyl), 4-(2,3-dihydro-benzo[b]thiophenyl), 5-(2,3-dihydro-benzo[b]thiophenyl), 6-(2,3-dihydro-benzo[b]thiophenyl), 7-(2,3-dihydro-benzo[b]thiophenyl), indolyl (1-indolyl, 2-indolyl, 3-indolyl, 4-indolyl, 5-indolyl, 6-indolyl, 7-indolyl), indazole (1-indazolyl, 3-indazolyl, 4-indazolyl, 5-indazolyl, 6-indazolyl, 7-indazolyl), benzimidazolyl (1-benzimidazolyl, 2-benzimidazolyl, 4-benzimidazolyl, 5-benzimidazolyl, 6-benzimidazolyl, 7-benzimidazolyl, 8-benzimidazolyl), benzoxazolyl (1-benzoxazolyl, 2-benzoxazolyl), benzothiazolyl (1-benzothiazolyl, 2-benzothiazolyl, 4-benzothiazolyl, 5-benzothiazolyl, 6-benzothiazolyl, 7-benzothiazolyl), carbazolyl (1-carbazolyl, 2-carbazolyl, 3-carbazolyl, 4-carbazolyl), 5H-dibenz[b,f]azepine (5H-dibenz[b,f]azepin-1-yl, 5H-dibenz[b,f]azepine-2-yl, 5H-dibenz[b,f]azepine-3-yl, 5H-dibenz[b,f]azepine-4-yl, 5H-dibenz[b,f]azepine-5-yl), 10,11-dihydro-5H-dibenz[b,f]azepine (10,11-dihydro-5H-dibenz[b,f]azepine-1-yl, 10,11-dihydro-5H-dibenz[b,f]azepine-2-yl, 10,11-dihydro-5H-dibenz[b,f]azepine-3-yl, 10,11-dihydro-5H-dibenz[b,f]azepine-4-yl, 10,11-dihydro-5H-dibenz[b,f]azepine-5-yl), furanyl (e.g. 2-furanyl, 3-furanyl, 4-furanyl and 5-furanyl), thienyl (e.g. 2-thienyl, 3-thienyl, 4-thienyl and 5-thienyl) optionally substituted with one or more substituents.

The term "optionally substituted" as used herein means an aryl residue as defined above or a C₁₋₆-alkyl residue as defined above that may be unsubstituted or may have 1 or more preferably 1 to 5 substituents, which are the same as or different from one another. Examples of these substituents include, halogen (fluorine, chlorine, bromine, iodine), hydroxyl, cyano, nitro, trifluoromethyl, carbamoyl, C₁₋₄-acyl (e.g. acetyl, propionyl, isopropionyl), C₁₋₆-alkoxy (e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy, and tert.butoxy), C₁₋₆-alkyl as defined above, C₁₋₆-alkoxycarbonyl (e.g. ones having 2 to 6 carbon atoms such as methoxycarbonyl, ethoxycarbonyl, and propoxycarbonyl), C₁₋₆-alkanoyloxy (e.g. ones having 2 to 6 carbon atoms such as acetyloxy, propionyloxy, isopropionyloxy), C₁₋₄-alkylthio (e.g. ones having 1 to 4 carbon atoms such as methylthio, ethylthio, propylthio, and isopropylthio), C₁₋₄-alkylsulphanyl (e.g. ones having 1-4 carbon atoms such as methylsulphanyl and ethylsulphanyl), C₁₋₄-alkylsulphonyl (e.g. ones having 1-4 carbon atoms such as methylsulphonyl and ethylsulphonyl), C₁₋₄-alkylamino (e.g. one having 1 to 4 carbon atoms such as methylamino, ethylamino, dimethylamino, and 1-pyrrolidinyl), aminoalkyl (e.g. one having an amino containing group connected to a C₁₋₆-alkyl group as defined above, such as 2-dimethylaminoethyl and 1-pyrrolidinylmethyl), aminoalkoxy (e.g. one having an amino containing group connected via a C₁₋₆-alkyl group as defined above to an oxygen atom, such as 2-dimethylaminoethoxy, 2-(4-morpholinyl)ethoxy and 1-pyrrolidinylmethoxy), aryl as defined above (e.g. phenyl and 4-pyridinyl), aryloxy (e.g. phenoxy), and aralkyloxy (e.g. benzyloxy).

20

The term "halogen" as used herein means fluorine, chlorine, bromine or iodine.

The term "perhalomethyl" as used herein means trifluoromethyl, trichloromethyl, tribromomethyl or triiodomethyl.

25

The term "perhalomethoxy" as used herein means trifluoromethoxy, trichloromethoxy, tribromomethoxy or triiodomethoxy.

The term "aralkyl" as used herein refers to an optionally substituted aryl residue as defined above, connected to an optionally substituted C₁₋₆-alkyl as defined above. Examples of the aralkyl residue include benzyl, 2-phenylethyl, 2-phenylethenyl, 3-(2-pyridyl)propyl, 3-phenylpropyl, 1-naphthylmethyl, 2-(1-naphthyl)ethyl and the like.

The term "C₁₋₆-alkoxy" as used herein, alone or in combination, refers to a straight or branched monovalent substituent comprising a C₁₋₆-alkyl group linked through an ether oxygen having its free valence bond from the ether oxygen and having 1 to 6 carbon atoms e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy, pentoxy.

5

The term "carbamoyl" as used herein refers to a carbamoyl which can be optionally substituted by one or two residues selected from the list consisting of optionally substituted C₁₋₆-alkyl as defined above, optionally substituted aryl as defined above and optionally substituted aralkyl as defined above.

10

In a preferred embodiment the invention relates to compounds of general formula (I) in which A is selected from benzene or thiophene.

15

In another preferred embodiment the invention relates to compounds of general formula (I), wherein R¹ is optionally substituted phenyl.

In another preferred embodiment the invention relates to compounds of general formula (I), wherein each one of R¹, R², and R³ is substituted with one or more substituents.

20

In another preferred embodiment the invention relates to compounds of general formula (I), wherein the substituents of R¹ is halogen, perhalomethyl, perhalomethoxy, or C₁₋₆-alkoxy.

25

In another preferred embodiment the invention relates to compounds of general formula (I), wherein the substituents of R¹ are selected from the group consisting of hydrogen, halogen, perhalomethyl, perhalomethoxy, or C₁₋₆-alkoxy.

In another preferred embodiment the invention relates to compounds of general formula (I), wherein the substituents of R¹ are selected from the group consisting of chloro, trifluoromethyl, methoxy, trifluoromethoxy.

30

In another preferred embodiment the invention relates to compounds of general formula (I), wherein R¹ is selected from the group consisting of phenyl, 4-chlorophenyl, 4-trifluoromethylphenyl, and 4-trifluoromethoxyphenyl.

In another preferred embodiment the invention relates to compounds of general formula (I), wherein R¹ is 2,3-dihydrobenzofuran or 4-methoxyphenyl.

5 In another preferred embodiment the invention relates to compounds of general formula (I), wherein R² is COR³ or (CH₂)_q-aryl, and q is 0, 1, 2, 3, 4, 5, or 6.

In another preferred embodiment the invention relates to compounds of general formula (I), wherein R³ is selected from the group consisting of phenyl, 3-methoxyphenyl, 4-methoxyphenyl, 4-chlorophenyl, 4-trifluoromethylphenyl, 4-(2-dimethylaminoethoxy)phenyl, 10 or 4-(2-morpholin-4-ylethoxy)phenyl.

In another preferred embodiment the invention relates to compounds of general formula (I), wherein R³ is selected from the group consisting of 4-methylphenyl, 3,4-dimethoxyphenyl, 4-ethoxyphenyl, 4-fluorophenyl, 4-trifluoromethylphenyl, dimethylaminophenyl, 4-(2-carboxyethenyl)phenyl, 4-(2-dimethylaminoethoxy)phenyl, 4-(2-morpholin-4-ylethoxy)phenyl, 1H-indol-5-yl, 3-chloro-4-methoxyphenyl, and 1H-benzimidazol-5-yl. 15


In another preferred embodiment the invention relates to compounds of general formula (I), wherein R⁴ and R⁵ independently is hydrogen, chloro, or methoxy.

20

In another preferred embodiment the invention relates to compounds of general formula (I), wherein n is 0 or 1 and m is 0 or 1.

In another preferred embodiment the invention relates to compounds of general formula (I), 25 wherein n is 0 and m is 0 or 1.

In a another preferred embodiment the invention relates to compounds of general formula (Ia):



30


(Ia)

wherein R⁷ is hydrogen, halogen, preferably chloro, methoxy, perhalomethoxy, preferably trifluoromethoxy, perhalomethyl, preferably trifluoromethyl, diloweralkylamino, preferably dimethylamino, or nitro,

5 and R⁶ and R⁸ independently are hydrogen, hydroxy, halogen, preferably chloro, bromo or fluoro, methyl, tert-butyl, phenyl, dimethylamino, methoxy, ethoxy, 2-dimethylaminoethoxy, 2-carboxyethenyl, 2-morpholin-4-ylethoxy, perhalomethyl, preferably trifluoromethyl, perhalomethoxy, preferably trifluoromethoxy, carboxy, cyano, methylthio, methylsulfonyl, acetamido, nitro, acetyl, acetoxy, or hydroxymethyl.

10

In another preferred embodiment the invention relates to compounds of general formula (Ia):



(Ia)


wherein R⁷ is halogen, perhalomethyl, or perhalomethoxy

15 and R⁶ and R⁸ independently are hydrogen, methoxy, ethoxy, hydroxy, fluoro, chloro, bromo, iodo, methyl, trifluoromethyl, dimethylamino, 2-carboxyethenyl, 2-dimethylaminoethoxy, or 2-morpholin-4-ylethoxy.

20 R⁷ is preferably selected from the group consisting of chloro, methoxy and trifluoromethyl, more preferably trifluoromethoxy.

Preferably, R⁶ and R⁸ are independently hydrogen, methoxy, chloro, trifluoromethyl, 2-dimethylaminoethoxy, or 2-morpholin-4-ylethoxy.

25 In another preferred embodiment the invention relates to compounds of general formula (Ib):




(Ib)

wherein R⁷ is as described above, and

R⁶ is hydroxy, halogen, preferably chloro or fluoro, methyl, dimethylamino, methoxy, ethoxy, perhalomethyl, preferably trifluoromethyl, perhalomethoxy, preferably trifluoromethoxy,

5 cyano, methylthio, acetyl, acetoxy, or hydroxymethyl.


In another preferred embodiment the invention relates to compounds of general formula (Ic):



wherein R⁷ is as defined above, and

10 R⁹ is 4-pyridyl, 5-hydroxypyrazin-2-yl, 5-chloro-6-hydroxypyridin-3-yl, 2-chloropyridin-3-yl, benzofuran-2-yl, benzothiophen-2-yl-, 7-methoxybenzofuran-2-yl, indolyl, preferably 1H-indol-5-yl, benzimidazol, preferably 1H-benzimidazol-5-yl or thienyl, preferably 5-chlorothiophen-2-yl.


15 In another preferred embodiment the invention relates to compounds of general formula (Ic):



wherein R⁷ is as defined above and R⁹ is indolyl, preferably 1H-indol-5-yl or benzimidazol, preferably 1H-benzimidazol-5-yl.


20 In the compounds of formula (Ic) R⁹ is preferably benzothiophen-2-yl, indolyl, preferably 1H-indol-5-yl, or benzimidazol, preferably 1H-benzimidazol-5-yl.

In another preferred embodiment the invention relates to compounds of general formula (Id):



wherein R⁷ is as defined above, and R¹⁰ is optionally substituted aralkyl as defined above, preferably 2-(4-methoxyphenyl)-ethenyl, 2-(3-methoxyphenyl)-ethenyl, 2-(4-chlorophenyl)-ethenyl, 2-(4-fluorophenyl)-ethenyl, 2-(4-trifluoromethylphenyl)-ethenyl, 2-(4-methoxyphenyl)-ethyl, 2-(4-chlorophenyl)-ethyl, 4-chlorobenzyl, 4-methoxybenzyl, 2-(2-furyl)-ethenyl, 2-(4,5-dimethyl-2-furyl)-ethenyl, 2-(5-methyl-2-furyl)-ethenyl, 2-(3-furyl)-ethenyl, 2-(2-thienyl)-ethenyl, or 2-(3-thienyl)-ethenyl.


10 In another preferred embodiment the invention relates to compounds of general formula (Id):



wherein R⁷ is as defined above, and R¹⁰ is 4-methoxyphenyl-2-ethenyl.

15 In the compounds of formula (Id) R⁷ is preferably as defined above and R¹⁰ is optionally substituted aralkyl as defined above, preferably 2-(4-methoxyphenyl)-ethenyl, 2-(2-furyl)-ethenyl, 2-(5-methyl-2-furyl)-ethenyl, 2-(3-furyl)-ethenyl, or 2-(3-thienyl)-ethenyl.

In another preferred embodiment the invention relates to compounds of general formula (Ie):



20


wherein R¹¹ is pyridyl, preferably 4-pyridyl, and

25 R⁶ and R⁸ independently are hydrogen, hydroxy, halogen, preferably chloro, bromo or fluoro, methyl, tert-butyl, phenyl, dimethylamino, methoxy, ethoxy, 2-dimethylaminoethoxy, 2-carboxyethenyl, 2-morpholin-4-ylethoxy, perhalomethyl, preferably trifluoromethyl, perhalo-

methoxy, preferably trifluoromethoxy, carboxy, cyano, methylthio, methylsulfonyl, acetamido, nitro, acetyl, acetoxy, or hydroxymethyl.


In another preferred embodiment the invention relates to compounds of general formula (If):

5



wherein R¹⁰ is optionally substituted aralkyl as defined above, preferably 2-(4-methoxyphenyl)-ethenyl, 2-(3-methoxyphenyl)-ethenyl, 2-(4-chlorophenyl)-ethenyl, 2-(4-fluorophenyl)-ethenyl, 2-(4-trifluoromethylphenyl)-ethenyl, 2-(4-methoxyphenyl)-ethyl, 2-(4-chlorophenyl)-ethyl, 4-chlorobenzyl, 4-methoxybenzyl, 2-(2-furyl)-ethenyl, 2-(4,5-dimethyl-2-furyl)-ethenyl, 2-(5-methyl-2-furyl)-ethenyl, 2-(3-furyl)-ethenyl, 2-(2-thienyl)-ethenyl, or 2-(3-thienyl)-ethenyl, and R¹¹ is pyridyl, preferably 4-pyridyl.

15 In another preferred embodiment the invention relates to compounds of general formula (Ig):




wherein R¹² is aryl or aralkyl, and

20

R⁶ and R⁸ independently are hydrogen, hydroxy, halogen, preferably chloro, bromo or fluoro, methyl, tert-butyl, phenyl, dimethylamino, methoxy, ethoxy, 2-dimethylaminoethoxy, 2-carboxyethenyl, 2-morpholin-4-ylethoxy, perhalomethyl, preferably trifluoromethyl, perhalomethoxy, preferably trifluoromethoxy, carboxy, cyano, methylthio, methylsulfonyl, acetamido, nitro, acetyl, acetoxy, or hydroxymethyl.

25

In another preferred embodiment the invention relates to compounds of general formula (Ih):



wherein R¹² is aryl, preferably 4-trifluoromethoxyphenyl, or aralkyl, preferably benzyl, and

5 R¹³ is aralkyl as defined above, preferably 2-(4-methoxyphenyl)-ethenyl, 2-(3-methoxyphenyl)-ethenyl, 2-(4-chlorophenyl)-ethenyl, 2-(4-fluorophenyl)-ethenyl, 2-(4-trifluoromethylphenyl)-ethenyl, 2-(4-methoxyphenyl)-ethyl, 2-(4-chlorophenyl)-ethyl, 4-chlorobenzyl, 4-methoxybenzyl, 2-(2-furyl)-ethenyl, 2-(4,5-dimethyl-2-furyl)-ethenyl, 2-(5-methyl-2-furyl)-ethenyl, 2-(3-furyl)-ethenyl, 2-(2-thienyl)-ethenyl, or 2-(3-thienyl)-ethenyl.

10

The most preferred compounds of the invention are:

(+)-[4-(4-Chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(4-methoxyphenyl)-methanone, (compound No. 1),

(-)-[4-(4-Chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(4-methoxyphenyl)-methanone, (compound No. 2),

(+)-[4-(4-Methoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(4-trifluoromethylphenyl)-methanone, (compound No. 3),

20 (-)-[4-(4-Methoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(4-trifluoromethylphenyl)-methanone, (compound No. 4),

[4-(4-Trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(4-methoxyphenyl)-methanone, (compound No. 5),

(+)-[4-(4-Trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(4-methoxyphenyl)-methanone, (compound No. 6),

(-)-[4-(4-Trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(4-methoxyphenyl)-methanone, (compound No. 7),

[4-(4-Trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(3-methoxyphenyl)-methanone, (compound No. 8),

30 (+)-[4-(4-Trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(3-methoxyphenyl)-methanone, (compound No. 9),

(-)-[4-(4-Trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(3-

methoxyphenyl)-methanone, (compound No. 10),
[4-(4-Chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-phenyl-methanone,
(compound No. 11),
(+)-[4-(4-Chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-phenyl-methanone,
5 (compound No. 12),
(-)-[4-(4-Chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-phenyl-methanone,
(compound No. 13),
(4-(2-Dimethylaminoethoxy)phenyl)-[4-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-
thieno[3,2-c]pyridin-5-yl]-methanone, (compound No. 14),
10 (+)-[4-(2-Dimethylaminoethoxy)phenyl)-[4-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-
thieno[3,2-c]pyridin-5-yl]-methanone, (compound No. 15),
(-)-[4-(2-Dimethylaminoethoxy)phenyl)-[4-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-
thieno[3,2-c]pyridin-5-yl]-methanone, (compound No. 16),
[4-(4-Chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-[4-(2-[2-morpholin-4-
15 ylethoxy)phenyl]-methanone, (compound No. 17),
(+)-[4-(4-Chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-[4-(2-[2-morpholin-4-
ylethoxy)phenyl]-methanone, (compound No. 18),
(-)-[4-(4-Chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-[4-(2-[2-morpholin-4-
ylethoxy)phenyl]-methanone, (compound No. 19),
20 [4-(4-Trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-[4-
dimethylaminophenyl]-methanone, (compound No 20),
3-{4-[4-(4-Chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine-5-carbonyl]phenyl}acrylic
acid, (compound No 21),
(4-Chlorophenyl)-[4-(4-chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-methanone,
25 both the racemate, the two pure enantiomers, and mixtures thereof (compound No 22),
[4-(4-Trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-[4-methoxyphenyl]-
methanone, (compound No. 24),
[4-(4-Trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-[4-methoxyphenyl]-
methanone, (compound No. 25),
30 [4-(2-Dimethylaminoethoxy)-phenyl]-[4-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-
thieno[3,2-c]pyridin-5-yl]-methanone, (compound No. 26),
[4-(2-Dimethylaminoethoxy)-phenyl]-[4-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-
thieno[3,2-c]pyridin-5-yl]-methanone, (compound No. 27),
[4-(4-Chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-[4-(2-morpholin-4-

ylethoxy)phenyl]-methanone, (compound No. 28),
[4-(4-Chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-[4-(2-morpholin-4-
ylethoxy)phenyl]-methanone, (compound No. 29),
[4-(4-Trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(4-
5 methoxyphenyl)-methanone, (compound No. 30),
[4-(4-Trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(4-
methoxyphenyl)-methanone, (compound No. 31),
[4-(4-Trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(4-
methoxyphenyl)-methanone, (compound No. 32),
10 [4-(4-Chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(1H-indol-5-yl)-methanone,
(compound No. 33),
(1H-Indol-5-yl)-[4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-
methanone, (compound No. 34),
[4-(4-Chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(4-fluorophenyl)-methanone,
15 (compound No. 35),
[4-(4-Trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(4-fluorophenyl)-
methanone, (compound No. 36),
4-(4-Chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-[4-(2-
dimethylaminoethoxy)phenyl]-methanone, (compound No. 37),
20 [4-(2-Dimethylaminoethoxy)phenyl]-[4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-
thieno[3,2-c]pyridin-5-yl]-methanone, (compound No. 38),
[7-Chloro-1-(2,3-dihydrobenzofuran-7-yl)-8-methoxy-1,2,4,5-tetrahydrobenzo[d]azepin-3-yl]-
[4-(2-dimethylaminoethoxy)-phenyl]-methanone, (compound No. 39),
[4-(3,4-Dimethoxyphenyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridin-6-yl]-[4-(2-
25 dimethylaminoethoxy)-phenyl]-methanone, (compound No. 40),
(3,4-Dimethoxyphenyl)-[4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-
5-yl]methanone, (compound No. 41),
(3-Chloro-4-methoxyphenyl)-[4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-
c]pyridin-5-yl]methanone, (compound No. 42),
30 (4-Ethoxyphenyl)-[4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-
yl]methanone, (compound No. 43),
(4-Methylphenyl)-[4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-
yl]methanone, (compound No. 44),
3-(4-Methoxyphenyl)-1-[4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-

5-yl]propenone, (compound No. 45),
(1H-Benzimidazol-5-yl)-[4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]methanone, (compound No. 46),
(4-Methoxyphenyl)-[4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-
5 methanone
[4-(4-Trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-[4-
methoxyphenyl]-methanone
[4-(4-Trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-[4-
methylsulfanylphenyl]-methanone
10 4-[4-(4-Trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine-5-carbonyl]benzoic
acid methyl ester
(4-Hydroxymethylphenyl)-[4-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]methanone
(4-Acetoxyphenyl)-[4-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-
15 yl]methanone
(4-Cyanophenyl)-[4-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-
yl]methanone
1-{4-[4-(4-Trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine-5-
carbonyl]phenyl}ethanone
20 3-Furan-2-yl-1-[4-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-
yl]propenone
3-(5-Methylfuran-2-yl)-1-[4-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-
yl]propenone
Benzo[b]thiophen-2-yl-1-[4-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-
25 5-yl]methanone
3-Furan-3-yl-1-[4-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-
yl]propenone
3-Thiophen-3-yl-1-[4-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-
yl]propenone
30 3-Thiophen-2-yl-1-[4-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-
yl]propenone
[4-(4-Methoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-[4-
methylsulfanylphenyl]methanone
4-[4-(4-Methoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine-5-carbonyl]benzonitrile

3-Furan-3-yl-1-[4-(4-methoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]propenone
(4-Methoxyphenyl)-[4-(4-methoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-
yl]methanone
(4-Fluorophenyl)-[4-(4-methoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-
5 yl]methanone
(4-Chlorophenyl)-[4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-
yl]methanone
(4-Methylsulfonylphenyl)-[4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-
c]pyridin-5-yl]methanone
10 (4-Dimethylaminophenyl)-[4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-
c]pyridin-5-yl]methanone
(4-Hydroxymethylphenyl)-[4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-
c]pyridin-5-yl]methanone
3-Furan-3-yl-1-[4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-
15 yl]propenone
4-(4-Chlorophenyl)-5-(4-methoxybenzyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine hydrochlo-
ride
[4-(4-Chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(4-
hydroxyphenyl)methanone
20 1-[4-(4-Chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-2-(4-
methoxyphenyl)ethanone
[4-(4-Chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(3-
dimethylaminophenyl)methanone
N-[4-[4-(4-Chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine-5-carbonyl]-
25 phenyl]acetamide
[4-(4-Chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(4-
methanesulfonylphenyl)methanone
2-(4-Chlorophenyl)-1-[4-(4-chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-
yl]ethanone
30 2-(4-Methoxyphenyl)-1-[4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-
5-yl]-ethanone
(3-Dimethylaminophenyl)-[4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-
c]pyridin-5-yl]-methanone

N-[4-[4-(4-Trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine-5-carbonyl]-phenyl]-acetamide

(4-Methanesulfonylphenyl)-[4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-methanone

5 2-(4-Chlorophenyl)-1-[4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-ethanone

Biphenyl-4-yl-[4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]methanone

(3,4-Dichlorophenyl)-[4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-10 10-yl]methanone

(4-tert-Butylphenyl)-[4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]methanone

Pyridin-4-yl-[4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]methanone

15 (5-Hydroxypyrazin-2-yl)-[4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]methanone

(5-Chloro-6-hydroxypyridin-3-yl)-[4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]methanone

3-(4,5-Dimethylfuran-2-yl)-1-[4-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-20 20-c]pyridin-5-yl]propenone

(1-Benzyl-1,2,3,4-tetrahydro-isoquinolin-2-yl)-(4-methoxyphenyl)methanone

(1-Benzyl-1,2,3,4-tetrahydro-isoquinolin-2-yl)-(4-chlorophenyl)methanone

(1H-Benzimidazol-5-yl)-(1-benzyl-1,2,3,4-tetrahydro-isoquinolin-2-yl)methanone

1-(1-Benzyl-1,2,3,4-tetrahydro-isoquinolin-2-yl)-3-furan-3-ylpropenone

25 1-(1-Benzyl-1,2,3,4-tetrahydro-isoquinolin-2-yl)-3-(4-methoxyphenyl)propenone

1-(1-Benzyl-1,2,3,4-tetrahydro-isoquinolin-2-yl)-3-(4-methoxyphenyl)propan-1-one

1-(1-Benzyl-1,2,3,4-tetrahydro-isoquinolin-2-yl)-2-(4-methoxyphenyl)ethanone

(5-Chlorothiophen-2-yl)-(4-pyridin-4-yl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl)methanone

(5-Chlorothiophen-2-yl)-[4-(4-dimethylaminophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-30 30-yl]methanone

(5-Chlorothiophen-2-yl)-[4-(4-nitrophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]methanone

(4-Hydroxymethylphenyl)-(4-phenyl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl)methanone

[4-(4-Dimethylaminophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl)-(4-hydroxymethylphenyl)-methanone

[4-(4-Nitrophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl)-(4-hydroxymethylphenyl)-methanone

5 (4-Chlorophenyl)-(4-phenyl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl)methanone

(4-Chlorophenyl)-(4-pyridin-4-yl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl)-methanone

(4-Chlorophenyl)-[4-(4-dimethylaminophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl)-methanone

(4-Chlorophenyl)-[4-(4-nitrophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl)-methanone

10 (4-Methoxyphenyl)-[4-phenyl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl)-methanone

(4-Methoxyphenyl)-(4-pyridin-4-yl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl)-methanone

[4-(4-Dimethylaminophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl)-(4-methoxyphenyl)-methanone

[4-(4-Dimethylaminophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl)-(4-methoxyphenyl)-

15 methanone

3-(4-Methoxyphenyl)-1-(4-phenyl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl)-propenone

(5-Chlorothiophen-2-yl)-(4-phenyl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl)-methanone

3-(4-Methoxyphenyl)-1-(4-pyridin-4-yl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl)-propenone

1-[4-(4-Dimethylaminophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl)-3-(4-

20 methoxyphenyl)-propenone

3-(4-Methoxyphenyl)-1-(4-(4-nitrophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl)-propenone

(4-Dimethylaminophenyl)-(4-phenyl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl)-methanone

(4-Dimethylaminophenyl)-(4-pyridin-4-yl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl)-

25 methanone

(4-Dimethylaminophenyl)-[4-(4-dimethylaminophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-methanone

(4-Dimethylaminophenyl)-[4-(4-nitrophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-methanone

30 (1H-Benzimidazol-5-yl)-(4-phenyl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl)-methanone

(1H-Benzimidazol-5-yl)-(4-phenyl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl)-methanone

(1H-Benzimidazol-5-yl)-[4-(4-nitrophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-methanone

(4-Fluorophenyl)-(4-phenyl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl)-methanone

(4-Fluorophenyl)-(4-pyridin-4-yl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl)-methanone
[4-(4-Dimethylaminophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(4-fluorophenyl)-
methanone

(4-Fluorophenyl)-[4-(4-nitrophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-methanone
5 (4-Bromophenyl)-(4-phenyl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl)-methanone
(4-Bromophenyl)-(4-pyridin-4-yl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl)-methanone
(4-Bromophenyl)-[4-(4-dimethylaminophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-
methanone

(4-Bromophenyl)-[4-(4-nitrophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-methanone
10 3-Furan-3-yl-1-(4-phenyl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl)-propenone
3-(3-Furan-3-yl)-1-(4-pyridin-4-yl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl)-propenone
1-[4-(4-Dimethylaminophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-3-(3-furan-3-yl)-
propenone

3-(3-Furan-3-yl)-1-[4-(4-nitrophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-propenone
15 [4-(4-Chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(4-hydroxyphenyl)-
methanone, less polar enantiomer,
[4-(4-Chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(4-hydroxyphenyl)-
methanone, more polar enantiomer,
(1H-Benzimidazol-5-yl)-[4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-
20 c]pyridin-5-yl]methanone, less polar enantiomer,
(1H-Benzimidazol-5-yl)-[4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-
c]pyridin-5-yl]methanone, more polar enantiomer,
(5-Chlorothiophen-2-yl)-[1-(4-trifluoromethoxyphenyl)-1,2,3,4-tetrahydroisoquinolin-2-yl]-
methanone

(4-Chlorophenyl)-[1-(4-trifluoromethoxyphenyl)-1,2,3,4-tetrahydroisoquinolin-2-yl]-methanone
25 (4-Methoxyphenyl)-[1-(4-trifluoromethoxyphenyl)-1,2,3,4-tetrahydroisoquinolin-2-yl]-
methanone
3-(4-Methoxyphenyl)-1-[1-(4-trifluoromethoxyphenyl)-1,2,3,4-tetrahydroisoquinolin-2-
yl]propenone

30 3-Furan-3-yl-1-[1-(4-trifluoromethoxyphenyl)-1,2,3,4-tetrahydroisoquinolin-2-yl]propenone
(4-Trifluoromethoxyphenyl)-[4-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-
c]pyridin-5-yl]methanone
(7-Methoxybenzofuran-2-yl)-[4-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-
c]pyridin-5-yl]methanone

Benzofuran-2-yl-[4-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]methanone

3-(4-Fluorophenyl)-1-[4-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]propanone

5 3-(4-Trifluoromethylphenyl)-1-[4-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]propanone

3-(3-Methoxyphenyl)-1-[4-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]propanone

3-(4-Chlorophenyl)-1-[4-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]propanone

10 3-(4-Methoxyphenyl)-1-[4-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]propan-1-one

3-(4-Chlorophenyl)-1-[4-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]propan-1-one

15

and salts thereof with a pharmaceutically acceptable acid or base.

The compounds of the present invention are normoglycaemic agents (i.e. compounds that are able to normalise blood glucose levels from hyper-/hypoglycemic conditions) that interact 20 with the glucose-6-phosphatase catalytic enzyme activity, and hence make them useful in the treatment and prevention of various diseases of the endocrinological system, especially ailments related to carbohydrate metabolism and especially the glucose metabolism, e.g. hyperglycaemia, diabetes mellitus, and especially non-insulin dependent diabetes mellitus (NIDDM) including long-term complications, such as retinopathy, neuropathy, nephropathy, 25 and micro- and macroangiopathy, and hypoglycaemia resulting from, e.g., glycogen storage disease (von Gierke's Disease all types). Moreover, the present compounds are useful in the prophylactic treatment of hyperlipidaemia, hypertension, liver and bile diseases, and atherosclerosis associated with diabetes. The present compounds are especially useful in the treatment of diseases associated with an increased or reduced activity of the glucose-6- 30 phosphatase complex, e. g. the G-6-Pase catalytic enzyme.

Accordingly, in another aspect the invention relates to a compound of the general formula I, Ia, Ib, Ic or a pharmaceutically acceptable acid addition salt or other salt as defined above thereof for use as a therapeutically acceptable substance, preferably for use as a therapeuti-

cally acceptable substance in the treatment of hyperglycaemia and treatment or prevention of diabetes.

Furthermore, the invention also relates to the use of the inventive compounds of formula I,

5 Ia, Ib, and Ic as medicaments useful for treating hyperglycaemia and treating or preventing diabetes.


In yet another aspect, the present invention relates to methods of preparing the above mentioned compounds. Methods of preparing compounds of general formula I comprises:

10

Method A:

When R^2 is COR³:

15 Reacting a compound of formula X with a compound of formula Y to form compounds of general formula Ib:




20 wherein R¹, R³, R⁴, R⁵, n, and m are as defined above and L is a leaving group and are selected from fluorine, chlorine, bromine, iodine, 1-imidazolyl, 1,2,4-triazolyl, 1-benzotriazolyl, 1-(4-aza benzotriazolyl)oxy, pentafluorophenoxy, N-succinyl, 3,4-dihydro-4-oxo-3-(1,2,3-benzotriazinyl)oxy, R³COO where R³ is as defined above, or any other leaving group known to act as a leaving group in acylation reactions. The base can be 25 either absent (i.e. compound X acts as a base) or triethylamine, N-ethyl-N,N-diisopropylamine, N-methylmorpholine, 2,6-lutidine, 2,2,6,6-tetramethylpiperidine, potassium carbonate, sodium carbonate, caesium carbonate or any other base known to be useful in acylation reactions.

30 Method B:

When R^2 is optionally substituted C_{1-6} alkyl or aralkyl:


a) Reacting a compound of formula X with a compound of formula Z in an alkylation reaction
 5 to form compounds of general formula I:



wherein R^1 , R^2 , R^4 , R^5 , n, and m are as defined above, M is a leaving group and is selected
 10 from chlorine, bromine, iodine, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy or any other group known to act as a leaving group in alkylation reactions. The base can be either absent (i.e. compound X acts as a base) or triethylamine, N-ethyl-N,N-diisopropylamine, N-methylmorpholine, 2,6-lutidine, 2,2,6,6-tetramethylpiperidine, potassium carbonate, sodium carbonate, caesium carbonate or any other base known to be
 15 useful in alkylation reactions.

Method C :

Reacting a compound of formula X with an aldehyde of formula Zz in a reductive alkylation
 20 reaction to form compounds of general formula I:



wherein R^1 , R^2 , R^4 , R^5 , n, and m are as defined above, R^{11} is as defined for R^2 but one (1)
 25 carbon atom shorter. The reducing agent can be selected from the following list: NaCNBH_3 , $\text{NaBH}(\text{OAc})_3$, diborane, BH_3 complexes (eg. with tetrahydrofuran or dimethylsulfide), metallic

sodium, or H₂/catalyst or any reductant known to be effective in the reductive alkylation reaction.

5 Or the compounds of formulae I, Ia, Ib, and Ic may be prepared by art-recognized procedures from known compounds or readily preparable intermediates.

The starting materials are either known compounds or compounds which may be prepared in analogy with the preparation of known compounds or in analogy with known methods as described by e.g Tupper D.E. et al., *J. Heterocyclic Chem.*, 33, 1123-9 (1996), Stokker G.E.,
10 *Tetrahedron Lett.*, 37, 5453-6 (1996), Nakagawa, M. et al., *Chem. Pharm. Bull.*, 41, 287-91 (1993), Singh H. et al., *Heterocycles*, 23, 107-10 (1985), Skinner W.A. et al., *Can. J. Chem.*, 43, 2251-3 (1965). P. Kumar et al., *J. Heterocyclic Chem.*, 19, 677-9 (1982), L. K. Lukonov et al., *Synthesis*, 1987, 204-6, A. L. Stanley & S. P. Stanforth, *J. Heterocyclic Chem.*, 31, 1399-1400 (1994), A. K. Bose et al., *J. Org. Chem.*, 56, 6968-70 (1991), K. Kementani et al., *Heterocycles*, 3, 311-41
15 (1975), E. Domonguez et al., *Tetrahedron*, 43, 1943-8 (1987), J. B. Bremner et al., *Aust. J. Chem.*, 41, 1815-26 (1988), M. J. O'Donnell et al., *Tetrahedron Lett.*, 23, 4259-62 (1982).

20 Pharmacological methods

The ability of compounds to inhibit glucose-6-phosphatase (G-6-Pase) catalytic enzyme activity from pig liver microsomes was tested in the following way:

25 Pig liver microsomes were prepared in a buffer containing 250 mM sucrose, 1 mM EDTA, 25 mM HEPES and 250 mg/l Bacitrazin (pH 7.5) essentially as described by Arion et al., 1980 (Arion, Lange, & Walls. 1980). Microsomes were kept at -80 °C until use.

30 Prior to measurement microsomes were treated with Triton X-100 (0.04%) ("disrupted microsomes"). G-6-Pase activity was assayed for 6 min at 30°C in a total volume of 325 µL containing 0.5 mM glucose-6-phosphate, 30 mM MES (pH 6.5), test compound and disrupted microsomes (0.05 mg). The reaction was terminated by addition of 100 µL Sigma phosphorus reagent (cat no 360-3C). This mixture was allowed to stand for 2 min, where the absorbance (A) was measured at 340 nm. All values were corrected for blank. The inhibitory effect was expressed as percent of control value, i.e. IC₅₀ is the concentration of a compound that
35 produces 50% inhibition.

The compounds of the invention are preferably characterized by having a glucose-6-phosphatase inhibitory activity corresponding to an IC₅₀ value of less than 100 μ M, more preferably less than 10 μ M, even more preferably less than 1 μ M, still more preferably less than 100 nM.

The compounds according to the invention are effective over a wide dosage range. In general satisfactory results are obtained with dosages from about 0.05 to about 1000 or 5000mg, preferably from about 0.1 to about 500 mg, per day. A most preferable dosage is about 5 mg to about 200 mg per day. The exact dosage will depend upon the mode of administration, form in which the compound is administered, the subject to be treated and the body weight of the subject to be treated, and the preference and experience of the physician or veterinarian in charge.

The dosage unit of the pharmaceutical compositions according to the invention typically contains from 0.05mg to 1000mg, preferably from 0.1mg to 500mg, or, preferably from 5mg to 200mg per day of the active ingredient, which is, preferably, a novel 4,5,6,7-tetrahydro-thieno[3,2-c]pyridine derivative as described herein or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric form thereof; or the active ingredient is a previously described 4,5,6,7-tetrahydro-thieno[3,2-c]pyridine derivative or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric form thereof.

25

The route of administration may be any route, which effectively transports the active compound to the appropriate or desired site of action, such as oral, nasal, pulmonary, transdermal or parenteral e.g. rectal, depot, subcutaneous, intravenous, intraurethral, intramuscular, intrapulmonary, intranasal, ophthalmic solution or an ointment, the oral route being preferred.

Optionally, the pharmaceutical composition of the invention may comprise a compound of formula I combined with one or more compounds exhibiting a different activity, e.g., a plasma lipid

lowering compounds, sulphonylurea like compounds, or other oral agents useful in the treatment of diabetes, or other pharmacologically active material.

Pharmaceutical compositions containing a compound of the present invention may be prepared by conventional techniques, e.g. as described in Remington: The Science and Practise of Pharmacy, 19th Ed., 1995. The compositions may appear in conventional forms, for example capsules, tablets, aerosols, solutions, suspensions or topical applications.

Typical compositions include a compound of formula I or a pharmaceutically acceptable acid addition salt or metal salt thereof, associated with a pharmaceutically acceptable excipient which may be a carrier or a diluent or be diluted by a carrier, or enclosed within a carrier which can be in form of a capsule, sachet, paper or other container. In making the compositions, conventional techniques for the preparation of pharmaceutical compositions may be used. For example, the active compound will usually be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier which may be in the form of a ampoule, capsule, sachet, paper, or other container. When the carrier serves as a diluent, it may be solid, semi-solid, or liquid material which acts as a vehicle, excipient, or medium for the active compound. The active compound can be adsorbed on a granular solid container for example in a sachet. Some examples of suitable carriers are water, salt solutions, alcohols, polyethylene glycols, polyhydroxyethoxylated castor oil, gelatine, lactose, amylose, magnesium stearate, talc, silicic acid, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, hydroxymethylcellulose and polyvinylpyrrolidone. Similarly, the carrier or diluent may include any sustained release material known in the art, such as glyceryl monostearate or glyceryl distearate, alone or mixed with a wax. The formulations may also include wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents or flavouring agents. The formulations of the invention may be formulated in any galenic dosage form so as to provide quick, sustained, or delayed release of the active ingredient after administration to the patient by employing procedures well known in the art. The pharmaceutical preparations can be sterilized and mixed, if desired, with auxiliary agents, emulsifiers, salt for influencing osmotic pressure, buffers and/or coloring substances and the like, which do not deleteriously react with the active compounds.

For administration, preferably nasal administration, the preparation may contain a compound of formula I, Ia, Ib or Ic dissolved or suspended in a liquid carrier, in particular an aqueous car-

rier, for aerosol application. The carrier may contain additives such as solubilizing agents, e.g. propylene glycol, surfactants, absorption enhancers such as lecithin (phosphatidylcholine) or cyclodextrin, or preservatives such as parabenes. For parenteral application, particularly suitable are injectable solutions or suspensions, preferably aqueous solutions with the active compound dissolved in polyhydroxylated castor oil. Tablets, dragees, or capsules having talc and/or a carbohydrate carrier or binder or the like are particularly suitable for oral application. Preferable carriers for tablets, dragees, or capsules include lactose, corn starch, and/or potato starch. A syrup or elixir can be used in cases where a sweetened vehicle can be employed.

10 A typical tablet, appropriate for use in this method, may be prepared by conventional tabletting techniques and contains:

Core:

15 Active compound (as free compound or salt thereof) 5.0 mg
Colloidal silicon dioxide (Aerosil) 1.5 mg
Cellulose, microcryst. (Avicel) 70 mg
Modified cellulose gum (Ac-Di-Sol) 7.5 mg
Magnesium stearate **Ad.**

20

Coating:

HPMC approx. 9 mg
*Mywacett 9-40 T approx. 0.9 mg

25 *Acylated monoglyceride used as plasticizer for film coating.

Due to their high degree of activity, the compounds of the invention may be administered to a mammal in need of such treatment, prevention, elimination, alleviation or amelioration of various diseases as mentioned above and especially of diseases of the endocrinological system such as hyperinsulinaemia and diabetes. Such mammals include both domestic animals, e.g. household pets, and non-domestic animals such as wildlife. Preferably the mammal is a human.

EXAMPLES


The process for preparing compounds of formula I, Ia, Ib, and/or Ic and preparations containing them is further illustrated in the following examples which, however, are not to be

5 construed as limiting.

EXAMPLE 1

10 Preparation of

[4-(4-Trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(4-methoxyphenyl)-methanone, (compound No. 5)



15

4-(4-Trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine (100 mg, 0.35 mmol) was dissolved in dichloromethane (0.5 mL) and triethylamine (0.5 mL) was added. To this solution p-anisoyl chloride (60 mg, 0.35 mmol) dissolved in dichloromethane (0.5 ml) was 20 added in one portion. The mixture was filtered and evaporated to afford 148 mg (100%) of the title compound.

MS (electrospray): m/z 418 (M+1)


HR-MS: Calculated for C₂₂H₁₈F₃NO₂S: 417.1010, Found: 417.0999.

25

EXAMPLE 2:

Preparation of

[4-(4-Trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(3-methoxyphenyl)-30 methanone, (compound No. 8)




5 4-(4-Trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine (100 mg, 0.35 mmol) was dissolved in dichloromethane (1 mL) and diisopropylethylamine (0.5 mL) was added. To this solution *m*-anisoyl chloride (50 μ L, 0.35 mmol) was added. The mixture was shaken overnight and evaporated to afford the title compound.

10 MS (electrospray): m/z 418 (M+1)
 HR-MS: Calculated for $C_{22}H_{18}F_3NO_2S$: 417.1010, Found: 417.1020.

EXAMPLE 3:

15 Preparation of
 [4-(4-Chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-phenyl-methanone,
 (compound No 11)



20


Benzoic acid (46 mg, 0.38 mmol) and 1-hydroxybenzotriazole (55 mg, 0.41 mmol) were dissolved in a mixture of dichloromethane (1 mL) and N,N-dimethylformamide (0.5 mL). N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (79 mg, 0.41 mmol) was added 25 and the mixture was shaken 0.5 hour at room temperature. 4-(4-Chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine (100 mg, 0.38 mmol) dissolved in dichloromethane (0.5 ml)

was added and the mixture was shaken at 1000 rpm for 3 hours. Water (1 mL) was added and the mixture was shaken at 1000 rpm overnight at room temperature. The organic phase was evaporated to give 129 mg (97%) of the title compound as an oil.

5 MS (electrospray): m/z 354 (M+1)
HR-MS: Calculated for C₂₀H₁₆CINOS: 353.0641, Found: 353.0646.

EXAMPLE 4:

10 Preparation of
(4-(2-Dimethylaminoethoxy)phenyl)-[4-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-methanone, (compound No 14)



15

Methyl 4-hydroxybenzoate (10 g, 66 mmoles) was dissolved in N,N-dimethylformamide (200 mL). Potassium carbonate (45 g, 0.33 moles) and 2-chloro-N,N-dimethylethylamine hydrochloride (14.2 g, 99 mmoles) were added and the resulting mixture was stirred vigorously at 20 room temperature for 7 days. More 2-chloro-N,N-dimethylethylamine hydrochloride (3 g, 20 mmoles) was added and stirring at room temperature was continued for 2 days. The reaction mixture was poured into water (600 mL) and extraction with ethyl acetate (2 x 200 mL), washing of the combined organic phases with water (200 mL), drying over MgSO₄ and evaporation afforded 11.9 g (81%) of methyl 4-(2-dimethylaminoethoxy)benzoate as an oil.

25

The above benzoate (11.9 g, 53 mmoles) was dissolved in 5 N hydrochloric acid and the mixture was heated at reflux temperature for 2 days. Cooling, filtration and washing with water afforded 8.63 g (66%) of 4-(2-dimethylaminoethoxy)benzoic acid hydrochloride as crystals.

The above benzoic acid (93 mg, 0.38 mmoles) was suspended in N,N-dimethylformamide (1 mL). 1-Hydroxybenzotriazole (55 mg, 0.42 mmoles), N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (79 mg, 0.42 mmoles), and triethylamine (106 μ L, 0.76 mmoles) were added and the resulting mixture was shaken at 1000 rpm for 1.5 hour. 4-(4-Trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine (108 mg, 0.38 mmoles) were added and the resulting mixture was shaken at 1000 rpm for 3 hours. Water (2 mL) and ethyl acetate (1 mL) were added and the resulting mixture was shaken at 1000 rpm for 15 minutes. The organic phase was evaporated to afford 144 mg (80%) of the title compound as an oil.

MS (electrospray): m/z 475.0 (M+1)

HR-MS: Calculated for $C_{25}H_{25}F_3N_2O_2S$: 474.1588, Found: 474.1580.


15

EXAMPLE 5:

Preparation of

[4-(4-Chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-[4-(2-morpholin-4-ylethoxy)phenyl]-methanone, (compound No 17)

20



25 Methyl 4-hydroxybenzoate (10 g, 66 mmoles) was dissolved in N,N-dimethylformamide (200 mL). Potassium carbonate (45 g, 0.33 moles) and 4-(2-chloroethyl)morpholine hydrochloride (18.3 g, 99 mmoles) were added and the resulting mixture was stirred vigorously at room temperature for 5 days. The reaction mixture was poured into water (500 mL) and extraction with ethyl acetate (2 x 250 mL), washing of the combined organic phases with water (200 mL), drying over $MgSO_4$ and evaporation afforded 16.8 g (96%) of methyl 4-(2-morpholin-4-ylmethoxy)benzoate as an oil.

The above benzoate (16.8 g, 63 mmoles) was dissolved in 5 N hydrochloric acid and the mixture was heated at reflux temperature for 16 hours. Cooling, filtration and washing with water afforded 15.6 g (86%) of 4-(2-morpholin-4-ylethoxy)benzoic acid hydrochloride as 5 crystals.

The above benzoic acid (111 mg, 0.38 mmoles) was suspended in N,N-dimethylformamide (1 mL). 1-Hydroxybenzotriazole (55 mg, 0.42 mmoles), N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (79 mg, 0.42 mmoles), and triethylamine (106 μ L, 0.76 10 mmoles) were added and the resulting mixture was shaken at 1000 rpm for 1.5 hour. 4-(4-Chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine (100 mg, 0.38 mmoles) was added and the resulting mixture was shaken at 1000 rpm for 3 hours. Water (2 mL) and ethyl acetate (1 mL) were added and the resulting mixture was shaken at 1000 rpm for 15 minutes. The organic phase was evaporated to afford 122 mg (66%) of the title compound as an oil.

15


MS (electrospray): m/z 483.0 (M+1)

HR-MS: Calculated for $C_{26}H_{27}ClN_2O_3S$: 482.1431, Found: 482.1430.

20 **EXAMPLE 6:**

Preparation of

(+)-[4-(4-Chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(4-methoxyphenyl)-methanone, (compound No 1)



25

[4-(4-Chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(4-methoxyphenyl)-methanone (30 mg) was dissolved in a 1:1 mixture of n-heptane and 2-propanol (5 mL) and 30 fractionated by HPLC (2 runs) using a 21.1 x 250 mm (*R,R*)-Whelk-O column (Regis). The


column was eluted isocratically with a 1:1 mixture of n-heptane and 2-propanol at a flow rate of 12 mL/min and fractions collected corresponding to 0.8 min/fraction. The eluting enantiomers were detected spectroscopically by measuring absorbance at a wavelength of 225 nm. Two eluting peaks were detected, one corresponding to T_R 44-50 min and one corresponding to T_R 62-72 min. Fractions from the two runs corresponding to T_R 44-50 min were 5 separately pooled and evaporated to yield 12.1 mg of the title compound.

100% ee (Determined by HPLC using a 4.6 x 250 mm (R,R)-Whelk-O column eluted with a 1:1 mixture of n-heptane and 2-propanol, the flow rate was 1 ml/min, eluting sample was 10 monitored spectroscopically at 225 and 245 nm, T_R 15.5 min).

EXAMPLE 7:

Preparation of

15 (-)-[4-(4-Chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(4-methoxyphenyl)-methanone, (compound No 2)



20

Fractions from the two runs of example 6 corresponding to T_R 62-72 min were separately pooled and evaporated to yield 12.5 mg of the title compound

98% ee (Conditions as described in example 6, T_R 20.8 min).


25

Optical rotation, using a Perkin Elmer Polarimeter (Model 241):
 $[\alpha]^{20}_D = -170.0$ (c=0.25, ethyl acetate).

30 **EXAMPLE 8:**

Preparation of

(+)-[4-(4-Methoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(4-trifluoromethylphenyl)-methanone, (compound No 3)



5

[4-(4-Methoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(4-trifluoromethylphenyl)-methanone (17 mg) was dissolved in a 1:2:2 mixture of ethyl acetate, n-heptane and 2-propanol (2.5 mL) and fractionated by HPLC using a 21.1 x 250 mm (R,R)-Whelk-O column (Regis). The column was eluted isocratically with a 1:1 mixture of n-heptane and 2-propanol at a flow rate of 10 mL/min and fractions collected corresponding to 1 min/fraction. The eluting enantiomers were detected spectroscopically by measuring absorbance at a wavelength of 225 nm. Two eluting peaks were detected, one corresponding to T_R 27-32 min and one corresponding to T_R 62-74 min. Fractions corresponding to T_R 27-32 min were pooled and evaporated to yield 7.1 mg of the title compound.

100% ee (Determined by HPLC using a 4.6 x 250 mm (R,R)-Whelk-O column eluted with a 1:1 mixture of n-heptane and 2-propanol, the flow rate was 1 mL/min, eluting sample was monitored spectroscopically at 225 and 245 nm, T_R 9.2 min)


Optical rotation, using a Perkin Elmer Polarimeter (Model 241),
 $[\alpha]^{20}_D = + 175.4$ (c=0.142, ethyl acetate).

25

EXAMPLE 9:

Preparation of

(-)-[4-(4-Methoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(4-trifluoromethylphenyl)-methanone, (compound No 4)




5 Fractions from the two runs of example 8 corresponding to T_R 62-74 min were separately pooled and evaporated to yield 6.8 mg of the title compound.

>99.5% ee (Conditions as described in example 8, T_R 17.0 min).

10 $[\alpha]^{20}_D = -170.6$ (c=0.136, ethyl acetate).

EXAMPLE 10:

15 [4-(4-Trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(4-dimethylaminophenyl)-methanone, (compound No 20)



20 4-Dimethylaminobenzoic acid (0.20 g, 1.2 mmol) was dissolved in N,N-dimethylformamide (3 ml) and 1-hydroxybenzotriazole (0.20 g, 1.5 mmol) was added. To the resulting mixture N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (0.28 g, 1.5 mmol) was added and the mixture was stirred at room temperature for 15 minutes. 4-(4-Trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine (0.41 g, 1.5 mmol) followed by diisopropylethylamine (0.42 ml, 2.4 mmol) were added and the mixture was stirred at room temperature for 16 hours. water (2 ml) was added and the mixture was extracted with ethyl acetate (2 x 5 ml).


The combined organic extracts were washed with saturated aqueous sodium chloride solution (4 ml), dried (MgSO_4) and concentrated in vacuo to afford the title compound.

MS (electrospray): m/z 431 (M+1)

5 HPLC (Method B): R_t = 29 min.

EXAMPLE 11:

10 3-{4-[4-(4-Chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine-5-carbonyl]phenyl}acrylic acid, (compound No 21)



15 (E)-4-(2-tert-Butoxycarbonylvinyl)benzoic acid (0.36 g, 1.4 mmol) was dissolved in N,N-dimethylformamide (50 ml) and 1-hydroxybenzoetiazole (0.20 g, 1.4 mmol) and N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (0.28 g, 1.4 mmol) were added and the mixture was stirred at room temperature for 20 minutes. 4-(4-Chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine (0.30 g, 1.2 mmol) and N-ethyl-N,N-diisopropylamine (420 20 μl , 2.4 mmol) were added to the mixture and stirring at room temperature was continued for 16 hours. The mixture was diluted with water (50 ml) and extracted with ethyl acetate (3 x 50 ml). The combined organic extracts were washed with saturated sodium chloride (80 ml), dried over MgSO_4 and concentrated in vacuo. The residue was purified by column chromatography over silica gel (60 ml) eluting with a mixture of ethyl acetate and heptane (1:2). 25 This afforded 0.56 g (97%) of 3-{4-[4-(4-Chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]-pyridine-5-carbonyl]phenyl}acrylic acid tert butyl ester as an oil.


¹H-NMR (300 MHz, DMSO-d_6): δ = 1.50 (9H, s), 2.8-3.1 (2H, m), 3.25 (1H, m), 3.65 (1H, m), 6.58 (1H, d), 6.78 (1H, bs), 6.87 (1H, d), 7.3-7.45 (7H, m), 7.60 (1H, d), 7.77 (2H, d).

The above tert-butyl ester (0.30 g, 0.62 mmol) was dissolved in dichloromethane (3 ml) and the mixture was cooled to 0 °C. At 0 °C trifluoroacetic acid (3 ml) was added and the mixture was stirred at 0 °C for 30 minutes. The mixture was concentrated in vacuo. The residue was dissolved in dichloromethane (5 ml), concentrated in vacuo dissolved again in methanol (5 ml) and concentrated in vacuo. 10.6 mg of the residue was dissolved in 750 µl methanol and purified by preparative HPLC using a Gilson binary gradient HPLC system equipped with 305 / 306 master/slave pumps, 117 UV detector and fraction collector. The eluting sample was detected at 210 and 225 nm. Flow rate was 15 ml/minute. The column was 20*250 mm ODS 10 µm (YMC) eluted with a gradient of acetonitrile (solvent B) and de-ionised water added 0.05% TFA (solvent A), 45% B to 100% B over 30 minutes. Fractions corresponding to 10 T_R 12 - 14 minutes were pooled to yield 8.3 mg of the title compound.

MS: m/z 424 (M+1).

15 **EXAMPLE 12:**

(4-Chlorophenyl)-[4-(4-chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-methanone, (compound No 22), less polar enantiomer



20


(4-Chlorophenyl)-[4-(4-chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-methanone (4.1 mg) was dissolved in a 1:2:4 mixture of ethyl acetate, heptane and 2-propanol (3.5 ml) 25 and fractionated by HPLC using a 21.1 x 250 mm (R,R)-Whelk-O column (Regis). The column was eluted isocratically with a 1:1 mixture of heptane and 2-propanol at a flow rate of 10 ml/min and fractions collected corresponding to 1 min/fraction. The eluting enantiomers were detected spectroscopically by measuring absorbance at a wavelength of 225 nm. Two eluting peaks were detected, one corresponding to T_R 28-32 minutes and one correspond-

ing to T_R 51-58 minutes. Fractions corresponding T_R 28-32 minutes were pooled and evaporated to yield 1.8 mg of the title compound.

100% ee (Determined by HPLC using a 4.6 x 250 mm (*R,R*)-Whelk-O column eluted with n-
5 heptane:2-propanol (1:1), the flow rate was 1 ml/min, eluting sample was monitored spectro-
scopically at 225 nm, T_R 9.9 min)

EXAMPLE 13:

10 (4-Chlorophenyl)-[4-(4-chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-methanone,
(compound No 23), more polar enantiomer




15

Fractions from example 12 corresponding to T_R 51-58 minutes were pooled and evaporated to yield 2.6 mg of the title compound.

20 99.5% ee (Conditions as described in example 12, T_R 15.5 min).

EXAMPLE 14:

25 [4-(4-Trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(4-methoxyphenyl)-
methanone, (compound No. 24), less polar enantiomer




[4-(4-Trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(4-methoxyphenyl)-methanone (11.2 mg) was dissolved in a 1:1 mixture of heptane and 2-propanol (2 ml) and fractionated by HPLC using a 21.1 x 250 mm (*R,R*)-Whelk-O column (Regis). The column was eluted isocratically with a 1:1 mixture of heptane and 2-propanol at a flow rate of 10 ml/min and fractions collected corresponding to 1 minute/fraction. The eluting enantiomers were detected spectroscopically by measuring absorbance at a wavelength of 225 nm. Two eluting peaks were detected, one corresponding to T_R 40-43 minutes and one corresponding to T_R 55-59 minutes. Fractions corresponding to T_R 40-43 minutes were pooled and evaporated to yield 4.0 mg of the title compound.

>99% ee (Determined by HPLC using a 4.6 x 250 mm (*R,R*)-Whelk-O column eluted with a 1:1 mixture of heptane and 2-propanol, the flow rate was 1 ml/min, eluting sample was monitored spectroscopically at 225 and 245 nm, T_R 12.6 min).

EXAMPLE 15:

[4-(4-Trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(4-methoxyphenyl)-methanone, (compound No. 25), more polar enantiomer




Fractions from example 14 corresponding to T_R 55-59 minutes were pooled and evaporated to yield 4.0 mg of the title compound.

5 99% ee (Conditions as described in example 14, T_R 16.4 min).

EXAMPLE 16:

10 [4-(2-Dimethylaminoethoxy)-phenyl]-[4-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-methanone, (compound No. 26), less polar enantiomer




15 [4-(2-Dimethylaminoethoxy)-phenyl]-[4-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-methanone (ca. 20 mg) was dissolved in a 1:1 mixture of heptane and 2-propanol (1 ml) and fractionated by HPLC using a 20 x 250 mm Chiralcel OD column. The column was eluted isocratically with a 7:3:0.01 mixture of heptane, 2-propanol and diethylamine at a flow rate of 6 ml/min and fractions collected corresponding to 1 min/fraction. The eluting enantiomers were detected spectroscopically by measuring absorbance at a wavelength of 225 nm. Two eluting peaks were detected, one corresponding to T_R 20-25 minutes and one corresponding to T_R 27-33 minutes. Fractions corresponding to T_R 20-25 minutes were pooled and evaporated to yield 8.4 mg of the title compound.

20 25 >99.9% ee (Determined by HPLC using a 4.6 x 250 mm Chiralcel OD column eluted with a 70:30:0.07 mixture of heptane, 2-propanol and diethylamine, the flow rate was 0.4 ml/min, eluting sample was monitored spectroscopically at 225 and 245 nm, T_R 15.4 min).

30 **EXAMPLE 17:**

[4-(2-Dimethylaminoethoxy)-phenyl]-[4-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-methanone, (compound No. 27), more polar enantiomer



5


Fractions from example 16 corresponding to T_R 27-33 minutes were pooled and evaporated
10 to yield 8.9 mg of the title compound.

>99% ee (Conditions as described in example 16, T_R 20.1 min).

EXAMPLE 18:

15

[4-(4-Chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-[4-(2-morpholin-4-ylethoxy)phenyl]-methanone, (compound No. 28), less polar enantiomer



20

[4-(4-Chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-[4-(2-morpholin-4-ylethoxy)phenyl]-methanone (ca. 10 mg) was dissolved in 3 ml a 15:15:1:0.2 mixture of heptane, 2-propanol, ethyl acetate and diethylamine (3 ml) and fractionated by HPLC using a
25 20 x 250 mm Chiralcel OD column. The column was eluted isocratically with a 70:30:0.1 mixture of heptane, 2-propanol and diethylamine at a flow rate of 6 ml/min and fractions col-

lected corresponding to 1 minute/fraction. The eluting enantiomers were detected spectroscopically by measuring absorbance at a wavelength of 225 nm. Two eluting peaks were detected, one corresponding to T_R 40-47 minutes and one corresponding to T_R 50-59 minutes. Fractions corresponding to T_R 40-47 minutes were pooled and evaporated to yield 4.1

5 mg of the title compound.


>99.9% ee (Determined by HPLC using a 4.6 x 250 mm Chiralcel OD column eluted with a 70:30:0.07 mixture of heptane, 2-propanol and diethylamine, the flow rate was 0.4 ml/min, eluting sample was monitored spectroscopically at 225 nm, T_R 22.9 min).

10

EXAMPLE 19:

[4-(4-Chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-[4-(2-morpholin-4-ylethoxy)phenyl]-methanone, (compound No. 29), more polar enantiomer

15



Fractions from example 18 corresponding to T_R 50-59 minutes were pooled and evaporated

20 to yield 4.0 mg of the title compound.


98% ee (Conditions as described in example 18, T_R 28.5 min).

EXAMPLE 20:

25

[4-(4-Trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-[4-methoxyphenyl]-methanone, (compound No. 30), less polar enantiomer

43




[4-(4-Trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(4-methoxyphenyl)-methanone (10 mg) was dissolved in 2-propanol (0.5 ml) and fractionated by HPLC using a 21.1 x 250 mm (*R,R*)-Whelk-O column (Regis). The column was eluted isocratically with a 1:1 mixture of heptane and 2-propanol at a flow rate of 10 ml/min and fractions collected corresponding to 1 minute/fraction. The eluting enantiomers were detected spectroscopically by measuring absorbance at a wavelength of 225 nm. Two eluting peaks were detected, one corresponding to T_R 24-30 minutes and one corresponding to T_R 41-47 minutes. Fractions corresponding to T_R 24-30 minutes were pooled and evaporated to yield 2.5 mg of the title compound.

>99.8% ee (Determined by HPLC using a 4.6 x 250 mm (*R,R*)-Whelk-O column eluted with a 1:1 mixture of n-heptane and 2-propanol, the flow rate was 1 ml/minute, eluting sample was monitored spectroscopically at 225 and 254 nm, T_R 12.0 min)

EXAMPLE 21:

[4-(4-Trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(4-methoxyphenyl)-methanone, (compound No. 31), more polar enantiomer



Fractions from example 20 corresponding to T_R 41-47 minutes were pooled and evaporated to yield 2.3 mg of the title compound.

99.1% ee (Conditions as described in example 20, T_R 15.8 min).

5


The compounds of this invention can also be prepared by parallel syntheses, for example by a method essentially as described above, e.g. as described in example 3. The 1-hydroxybenzotriazole or another hydroxy azole known to be effective as alcohol component in active ester mediated amide coupling reactions can either be present in the reaction or it 10 can be omitted depending on the substitution on the carboxylic acid part. This will be recognised by those skilled in the art.

A general procedure for parallel preparation of compounds of the invention is given in example 22:

15

EXAMPLE 22:

20 [4-(4-Trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(4-methoxyphenyl)-methanone, (compound No. 32)



25 A solution of 4-(4-Trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) was added to a solution of 4-methoxybenzoic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol). To this solution 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) was added. The mixture was shaken overnight at

room temperature at 1000 rpm, added saturated NaCl (2 ml), and extracted with ethyl acetate (2 x 1 ml). The combined organic extracts were evaporated to afford the title compound.


MS (electrospray): m/z 434 (M+1)

5 HPLC (Method B): R_t = 33.2 min.

EXAMPLE 23:

[4-(4-Chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(1H-indol-5-yl)-methanone,

10 (compound No. 33)



15 Similarly as described in example 22 using a solution of 4-(4-chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of indole-5-carboxylic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

20


MS (electrospray): m/z 393 (M+1)

HPLC (Method B): R_t = 30.7 min.

EXAMPLE 24:

25

(1H-Indol-5-yl)-[4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-methanone, (compound No. 34)




Similarly as described in example 22 using a solution of 4-(4-Trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of indole-5-carboxylic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

10 MS (electrospray): m/z 443 (M+1)
HPLC (Method B): R_t = 31.5 min.

EXAMPLE 25:

15 [4-(4-Chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(4-fluorophenyl)-methanone,
(compound No. 35)



20


Similarly as described in example 22 using a solution of 4-(4-chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 4-fluorobenzoic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

MS (electrospray): m/z 372 (M+1)

HPLC (Method B): R_t = 32.6 min.

5 **EXAMPLE 26:**

[4-(4-Trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(4-fluorophenyl)-methanone, (compound No. 36)



10

Similarly as described in example 22 using a solution of 4-(4-trifluoromethoxyphenyl)-4,5,6,7-

tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a

15 solution of 4-fluorobenzoic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and

0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in

dichloromethane (1.73 g in 8.3 ml) affords the title compound.

MS (electrospray): m/z 422 (M+1)


20 HPLC (Method B): R_t = 32.2 min.

EXAMPLE 27:

[4-(4-Chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-[4-(2-

25 dimethylaminoethoxy)phenyl]-methanone, (compound No. 37)

48



Similarly as described in example 22 using a solution of 4-(4-chlorophenyl)-4,5,6,7-
 5 tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a suspension of 4-(2-dimethylaminoethoxy)benzoic acid hydrochloride in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), triethylamine (42 μ l), and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.


10

MS (electrospray): m/z 441 (M+1)

HPLC (Method B): R_t = 23.4 min.**EXAMPLE 28:**

15

[4-(2-Dimethylaminoethoxy)phenyl]-[4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-methanone, (compound No. 38)



20

Similarly as described in example 22 using a solution of 4-(4-trifluoromethoxyphenyl)-4,5,6,7-
 5 tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a suspension of 4-(2-dimethylaminoethoxy)benzoic acid hydrochloride in N,N-dimethyl-
 25 formamide (0.375 M, 0.4 ml, 0.15 mmol), triethylamine (42 μ l), and 0.25 ml of a suspension


of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

MS (electrospray): m/z 491 (M+1)

5 HPLC (Method B): R_t = 24.9 min.

EXAMPLE 29:

10 [7-Chloro-1-(2,3-dihydrobenzofuran-7-yl)-8-methoxy-1,2,4,5-tetrahydrobenzo[d]azepin-3-yl]-[4-(2-dimethylaminoethoxy)-phenyl]-methanone, (compound No. 39)



15 Similarly as described in example 22 using a solution of 7-chloro-1-(2,3-dihydrobenzofuran-7-yl)-8-methoxy-1,2,4,5-tetrahydrobenzo[d]azepine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a suspension of 4-(2-dimethylaminoethoxy)benzoic acid hydrochloride in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), triethylamine (42 μ l), and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.


MS (electrospray): m/z 521 (M+1)

HPLC (Method B): R_t = 22.9 min.

25 **EXAMPLE 30:**

[4-(3,4-Dimethoxyphenyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridin-6-yl]-[4-(2-dimethylaminoethoxy)-phenyl]-methanone, (compound No. 40)

50



Similarly as described in example 22 using a solution of 4-(3,4-Dimethoxyphenyl)-4,5,6,7-
 5 tetrahydro-thieno[2,3-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a
 suspension of 4-(2-dimethylaminoethoxy)benzoic acid hydrochloride in N,N-
 dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), triethylamine (42 μ l), and 0.25 ml of a sus-
 pension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane
 (1.73 g in 8.3 ml) affords the title compound.

10


MS (electrospray): m/z 467 (M+1)

HPLC (Method B): R_t = 18.1 min.

15 EXAMPLE 31:

(3,4-Dimethoxyphenyl)-[4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-
 5-yl]methanone, (compound No. 41)

20



Similarly as described in example 22 using a solution of 4-(4-trifluoromethoxyphenyl)-4,5,6,7-
 25 tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a
 solution of 3,4-dimethoxybenzoic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15

mmol), and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.


MS (electrospray): m/z 464 (M+1)

5 HPLC (Method B): R_t = 32.1 min

EXAMPLE 32:

(3-Chloro-4-methoxyphenyl)-[4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-

10 c]pyridin-5-yl]methanone, (compound No. 42)



15 Similarly as described in example 22 using a solution of 4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 3-chloro-4-methoxybenzoic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

20

MS (electrospray): m/z 468 (M+1)


HPLC (Method B): R_t = 34.4 min

EXAMPLE 33:

25

(4-Ethoxyphenyl)-[4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]methanone, (compound No. 43)

52




Similarly as described in example 22 using a solution of 4-(4-trifluoromethoxyphenyl)-4,5,6,7-
 5 tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a
 solution of 4-ethoxybenzoic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol),
 and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride
 in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

10 MS (electrospray): m/z 448 (M+1)
 HPLC (Method B): R_t = 35.1 min

EXAMPLE 34:

15 (4-Methylphenyl)-[4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-
 yl]methanone, (compound No. 44)




20 Similarly as described in example 22 using a solution of 4-(4-trifluoromethoxyphenyl)-4,5,6,7-
 tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a
 solution of 4-methylbenzoic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol),
 and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride
 25 in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

MS (electrospray): m/z 418 (M+1)

HPLC (Method B): R_t = 35.2 min

5 **EXAMPLE 35:**

3-(4-Methoxyphenyl)-1-[4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]propenone, (compound No. 45)



10


Similarly as described in example 22 using a solution of 4-(4-trifluoromethoxy-phenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 4-methoxycinnamic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

MS (electrospray): m/z 460 (M+1)

20 HPLC (Method B): R_t = 35.0 min

EXAMPLE 36:

(1H-Benzimidazol-5-yl)-[4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]methanone, (compound No. 46)




Similarly as described in example 22 using a solution of 4-(4-trifluoromethoxyphenyl)-4,5,6,7-
 5 tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a
 solution of benzimidazole-5-carboxylic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15
 mmol), and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide
 hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

10 MS (electrospray): m/z 444 (M+1)
 HPLC (Method B): R_t = 23.1 min

EXAMPLE 37:

15 (4-Methoxyphenyl)-[4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-
 methanone



4-Methoxybenzoic acid (0.64 g, 4.2 mmol) was dissolved in N,N-dimethylformamide (25 ml)
 and 1-hydroxybenzotriazole (0.71 g, 5 mmol) was added followed by N-(3-
 dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (0.96 g, 5 mmol). The resulting
 mixture was stirred at room temperature for 30 minutes. 4-(4-Trifluoromethoxyphenyl)-
 25 4,5,6,7-tetrahydro-thieno[3,2-c]pyridine (1.5 g, 5 mmol) followed by N,N-

diisopropylethylamine (1.4 ml, 8.4 mmol) were added and the resulting mixture was stirred at room temperature for 16 hours. Water (10 ml) was added and the mixture was extracted with diethyl ether (3 x 20 ml). The combined organic extracts were washed with saturated aqueous ammonium chloride (20 ml), dried over MgSO_4 and concentrated *in vacuo*. The residue 5 was purified by column chromatography over silica gel eluting with a mixture of ethyl acetate and heptane (1:2). The pure fractions were pooled and concentrated *in vacuo*. The residue was crystallised from a mixture of methyl tert-butyl ether and heptane to afford 2.13 g (98%) of the title compound.

10 M.p. 68 - 70 °C.

Calculated for $\text{C}_{22}\text{H}_{18}\text{F}_3\text{NO}_3\text{S} \cdot 0.25\text{H}_2\text{O}$:


C, 60.34%; H, 4.26%; N, 3.20%. Found:

C, 60.35%; H, 4.38%; N, 3.07%;

15 C, 60.34%; H, 4.33%; N, 3.09%.

EXAMPLE 38:

[4-(4-Trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(4-methoxyphenyl)-methanone




25 Similarly as described in example 22 using a solution of 4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 4-methoxy-3-nitrobenzoic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

MS (electrospray): m/e: 479 (M+1)

HPLC (method B): R_t = 32.5 min.

5 **EXAMPLE 39:**

[4-(4-Trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(4-methylsulfonylphenyl)-methanone



10


Similarly as described in example 22 using a solution of 4-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a
15 solution of 4-methylsulfonylbenzoic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

MS (electrospray): m/z: 434 (M+1)

20 HPLC (method B): R_t = 33.5 min.

EXAMPLE 40:

25 4-[4-(4-Trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine-5-carbonyl]benzoic acid methyl ester




Similarly as described in example 22 using a solution of 4-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of mono methyl terephthalic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

10 MS (electrospray): m/z: 446 (M+1)
HPLC (method B): R_t = 31.9 min.

EXAMPLE 41:

15 (4-Hydroxymethylphenyl)-[4-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]methanone



20

Similarly as described in example 22 using a solution of 4-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 4-hydroxymethylbenzoic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.


MS (electrospray): m/z: 418 (M+1)

HPLC (method B): R_t = 27.2 min.

5 **EXAMPLE 42:**

(4-Acetoxyphenyl)-[4-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]methanone

10




Similarly as described in example 22 using a solution of 4-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a
15 solution of 4-acetoxybenzoic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

20 MS (electrospray): m/z: 446 (M+1)

HPLC (method B): R_t = 30.7 min.

EXAMPLE 43:

(4-Cyanophenyl)-[4-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]methanone
25




Similarly as described in example 22 using a solution of 4-(4-trifluoromethylphenyl)-4,5,6,7-
 5 tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a
 solution of 4-cyanobenzoic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and
 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in
 dichloromethane (1.73 g in 8.3 ml) affords the title compound.

10 MS (electrospray): m/z: 413 (M+1)
 HPLC (method B): R_t = 30.6 min.

EXAMPLE 44:

15 1-{4-[4-(4-Trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine-5-
 carbonyl]phenyl}ethanone




Similarly as described in example 22 using a solution of 4-(4-trifluoromethylphenyl)-4,5,6,7-
 tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a
 solution of 4-acetylbenzoic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and
 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in
 25 dichloromethane (1.73 g in 8.3 ml) affords the title compound.

MS (electrospray): m/z: 430 (M+1)

HPLC (method B): R_t = 30.5 min.

5 **EXAMPLE 45:**

3-Furan-2-yl-1-[4-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]propenone



10


Similarly as described in example 22 using a solution of 4-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a
15 solution of 3-(furan-2-yl)acrylic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

MS (electrospray): m/z: 404 (M+1)

20 HPLC (method B): R_t = 32.2 min.

EXAMPLE 46:

3-(5-Methylfuran-2-yl)-1-[4-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]propenone




Similarly as described in example 22 using a solution of 4-(4-trifluoromethylphenyl)-4,5,6,7-
5 tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a
solution of 3-(5-methylfuran-2-yl)acrylic acid in N,N-dimethylformamide (0.375 M, 0.4 ml,
0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide
hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

10 MS (electrospray): m/z: 418 (M+1)
HPLC (method B): R_t = 33.7 min.

EXAMPLE 47:

15 Benzo[b]thiophen-2-yl-1-[4-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-
5-yl]methanone




20 Similarly as described in example 22 using a solution of 4-(4-trifluoromethylphenyl)-4,5,6,7-
tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a
solution of benzo[b]thiophen-2-yl-carboxylic acid in N,N-dimethylformamide (0.375 M, 0.4 ml,
0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide
25 hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

MS (electrospray): m/z: 444 (M+1)

HPLC (method B): R_t = 35.1 min.

5 **EXAMPLE 48:**

3-Furan-3-yl-1-[4-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]propenone



10


Similarly as described in example 22 using a solution of 4-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a
15 solution of 3-furan-3-ylacrylic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

MS (electrospray): m/z: 404 (M+1)

20 HPLC (method B): R_t = 31.4 min.

EXAMPLE 49:

3-Thiophen-3-yl-1-[4-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]propenone




Similarly as described in example 22 using a solution of 4-(4-trifluoromethylphenyl)-4,5,6,7-
 5 tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a
 solution of 3-thiophen-3-ylacrylic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15
 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hy-
 drochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

10 MS (electrospray): m/z: 420 (M+1)
 HPLC (method B): R_t = 32.8 min.

EXAMPLE 50:

15 3-Thiophen-2-yl-1-[4-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-
 yl]propanone




20 Similarly as described in example 22 using a solution of 4-(4-trifluoromethylphenyl)-4,5,6,7-
 tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a
 solution of 3-thiophen-3-ylacrylic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15
 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hy-
 drochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

MS (electrospray): m/z: 420 (M+1)

HPLC (method B): R_t = 33.3 min.

5 **EXAMPLE 51:**

[4-(4-Methoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(4-methylsulfonylphenyl)methanone



10

Similarly as described in example 22 using a solution of 4-(4-methoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a
15 solution of 4-methylsulfonylbenzoic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

MS (electrospray): m/z: 396 (M+1)


20 HPLC (method B): R_t = 29.5 min.

EXAMPLE 52:

4-[4-(4-Methoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine-5-carbonyl]benzonitrile

25

65




Similarly as described in example 22 using a solution of 4-(4-methoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 4-cyanobenzoic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

MS (electrospray): m/z: 375 (M+1)
HPLC (method B): R_t = 26.2 min.

EXAMPLE 53:

15 3-Furan-3-yl-1-[4-(4-methoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]propanone




20 Similarly as described in example 22 using a solution of 4-(4-methoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 3-(furan-3-yl)acrylic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

MS (electrospray): m/z: 366 (M+1)
HPLC (method B): R_t = 26.9 min.

EXAMPLE 54:

5

(4-Methoxyphenyl)-[4-(4-methoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]methanone



10

Similarly as described in example 22 using a solution of 4-(4-methoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 4-methoxybenzoic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) 15 and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.


MS (electrospray): m/z: 380 (M+1)
HPLC (method B): R_t = 27.6 min.

20

EXAMPLE 55:

(4-Fluorophenyl)-[4-(4-methoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]methanone

25




Similarly as described in example 22 using a solution of 4-(4-methoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a
5 solution of 4-fluorobenzoic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

MS (electrospray): m/z: 368 (M+1)
10 HPLC (method B): R_t = 27.7 min.

EXAMPLE 56:

(4-Chlorophenyl)-[4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-
15 yl]methanone




20 Similarly as described in example 22 using a solution of 4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 4-chlorobenzoic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

25 MS (electrospray): m/z: 438 (M+1)
HPLC (method B): R_t = 32.8 min.

EXAMPLE 57:

(4-Methylsulfonylphenyl)-[4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]methanone




5

Similarly as described in example 22 using a solution of 4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a 10 solution of 4-methylsulfonylbenzoic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

15 MS (electrospray): m/z: 450 (M+1)
HPLC (method B): R_t = 32.6 min.

EXAMPLE 58:

(4-Dimethylaminophenyl)-[4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]methanone



Similarly as described in example 22 using a solution of 4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 4-dimethylaminobenzoic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

5


MS (electrospray): m/z: 447 (M+1)

HPLC (method B): R_t = 27.1 min.

10 **EXAMPLE 59:**

(4-Hydroxymethylphenyl)-[4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]methanone

15



Similarly as described in example 22 using a solution of 4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 4-hydroxymethylbenzoic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.


20

MS (electrospray): m/z: 434 (M+1)

25 HPLC (method B): R_t = 26.6 min.

EXAMPLE 60:

3-Furan-3-yl-1-[4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]propenone



5

Similarly as described in example 22 using a solution of 4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 3-(3-furan-3-yl)acrylic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

MS (electrospray): m/z: 420 (M+1)


HPLC (method B): R_t = 30.4 min.

15

EXAMPLE 61:

4-(4-Chlorophenyl)-5-(4-methoxybenzyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine hydrochloride

20



4-(4-Chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine (0.10 g, 0.38 mmol) was dissolved in N,N-dimethylformamide (0.5 ml) and triethylamine (110 µl, 0.76 mmol) and 4-methoxybenzyl chloride (51 µl, 0.38 mmol) were added and the resulting mixture was


shaken at 1000 rpm for 3 days. Water (2 ml) was added and the mixture was extracted with ethyl acetate (2 x 1 ml). The combined organic extracts were concentrated *in vacuo*. The residue was purified by preparative thin layer chromatography eluting with a mixture of ethyl acetate and heptane (1:4) to afford the free base. This was dissolved in diethyl ether and 1N 5 HCl in diethyl ether was added drop wise to complete precipitation to afford 52 mg (34%) of the title compound.

HPLC-MS: R_t = 9.57 min. m/z = 370 (M+1).

10 **EXAMPLE 62:**

[4-(4-Chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(4-hydroxyphenyl)methanone

15



4-Hydroxybenzoic acid (1.3 g, 9.6 mmol) was dissolved in N,N-dimethylformamide (25 ml) 20 and 1-hydroxybenzotriazole (1.3 g, 9.6 mmol) was added followed by N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (1.8 g, 9.6 mmol), 4-(4-chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine (2.0 g, 8 mmol) and N,N-diisopropylethylamine (2.5 ml, 16 mmol). The resulting mixture was stirred at room temperature for 16 hours. Water (200 ml) was added and the mixture was extracted with diethyl 25 ether (3 x 100 ml). The combined organic extracts were washed with saturated aqueous sodium chloride (150 ml), dried over $MgSO_4$ and concentrated *in vacuo*. The residue was purified by column chromatography over silica gel eluting with a mixture of ethyl acetate and heptane (1:1). The pure fractions were pooled and concentrated *in vacuo* to afford 3.14 g (100%) of the title compound.

30

M.p. 202 - 207 °C.

Calculated for $C_{20}H_{16}ClNO_2S$:

C, 64.95%; H, 4.36%; N, 3.79%. Found:


5 C, 64.54%; H, 4.74%; N, 4.29%;
C, 64.63%; H, 4.76%; N, 4.28%.

HPLC-MS: R_t = 14.18 min. m/z: 370 (M+1)

10 **EXAMPLE 63:**

1-[4-(4-Chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-2-(4-methoxyphenyl)ethanone

15




Similarly as described in example 22 using a solution of 4-(4-chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a 20 solution of 4-methoxyphenylacetic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

25 MS (electrospray): m/z: 398 (M+1)
HPLC (method B): R_t = 32.2 min.

EXAMPLE 64:

30 [4-(4-Chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(3-dimethylaminophenyl)methanone



5 Similarly as described in example 22 using a solution of 4-(4-chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 3-dimethylaminobenzoic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.


10

MS (electrospray): m/z: 397 (M+1)
 HPLC (method B): R_t = 25.9 min.

EXAMPLE 65:

15

N-{4-[4-(4-Chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine-5-carbonyl]}-phenylacetamide



20

Similarly as described in example 22 using a solution of 4-(4-chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 4-acetamidobenzoic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.


MS (electrospray): m/z: 411 (M+1)

HPLC (method B): R_t = 27.2 min.

5 **EXAMPLE 66:**

[4-(4-Chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(4-methanesulfonylphenyl)methanone

10




Similarly as described in example 22 using a solution of 4-(4-chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a 15 solution of 4-methanesulfonylbenzoic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

20 MS (electrospray): m/z: 432 (M+1)

HPLC (method B): R_t = 28.1 min.

EXAMPLE 67:

25 2-(4-Chlorophenyl)-1-[4-(4-chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]ethanone




Similarly as described in example 22 using a solution of 4-(4-chlorophenyl)-4,5,6,7-
 5 tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a
 solution of 4-chlorophenylacetic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol)
 and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

10 MS (electrospray): m/z: 402 (M+1)
 HPLC (method B): R_t = 34.5 min.

EXAMPLE 68:

15 2-(4-Methoxyphenyl)-1-[4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-
 5-yl]-ethanone



20 Similarly as described in example 22 using a solution of 4-(4-trifluoromethoxyphenyl)-4,5,6,7-
 tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a
 solution of 4-chlorophenylacetic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol)
 and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.


MS (electrospray): m/z: 448 (M+1)

HPLC (method B): R_t = 32.9 min.

EXAMPLE 69:

5

(3-Dimethylaminophenyl)-[4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-methanone



10

Similarly as described in example 22 using a solution of 4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 3-dimethylaminobenzoic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

MS (electrospray): m/z: 447 (M+1)


HPLC (method B): R_t = 27.2 min.

20

EXAMPLE 70:

N-[4-[4-(4-Trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine-5-carbonyl]-phenyl]-acetamide

25




Similarly as described in example 22 using a solution of 4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 4-acetamidobenzoic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

10 MS (electrospray): m/z: 461 (M+1)
 HPLC (method B): R_t = 28.2 min.

EXAMPLE 71:

15 (4-Methanesulfonylphenyl)-[4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-methanone



20 Similarly as described in example 22 using a solution of 4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 4-methanesulfonylbenzoic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15

mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.


MS (electrospray): m/z: 482 (M+1)

5 HPLC (method B): R_t = 29.1 min.

EXAMPLE 72:

2-(4-Chlorophenyl)-1-[4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-

10 yl]-ethanone



15 Similarly as described in example 22 using a solution of 4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 4-chlorophenylacetic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

20


MS (electrospray): m/z: 452 (M+1)

HPLC (method B): R_t = 34.9 min.

EXAMPLE 73:

25

Biphenyl-4-yl-[4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]methanone




Similarly as described in example 22 using a solution of 4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 4-biphenylcarboxylic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

10 MS (electrospray): m/z: 480 (M+1)
HPLC (method B): R_t = 36.7 min.

EXAMPLE 74:

15 (3,4-Dichlorophenyl)-[4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]methanone



Similarly as described in example 22 using a solution of 4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 3,4-dichlorobenzoic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol)

and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.


MS (electrospray): m/z: 472 (M+1)

5 HPLC (method B): R_t = 36.2 min.

EXAMPLE 75:

(4-tert-Butylphenyl)-[4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-

10 yl]methanone



20

MS (electrospray): m/z: 460 (M+1)

HPLC (method B): R_t = 37.0 min.

EXAMPLE 76:

25

Pyridin-4-yl-[4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]methanone




Similarly as described in example 22 using a solution of 4-(4-trifluoromethoxyphenyl)-4,5,6,7-
 5 tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a
 solution of pyridine-4-carboxylic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol)
 and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

10 MS (electrospray): m/z: 405 (M+1)
 HPLC (method B): R_t = 23.9 min.

EXAMPLE 77:

15 (5-Hydroxypyrazin-2-yl)-[4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-
 5-yl]methanone



Similarly as described in example 22 using a solution of 4-(4-trifluoromethoxyphenyl)-4,5,6,7-
 tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a
 solution of 5-hydroxypyrazine-2-carboxylic acid in N,N-dimethylformamide (0.375 M, 0.4 ml,


0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

MS (electrospray): m/z: 422 (M+1)

5 HPLC (method B): R_t = 26.0 min.

EXAMPLE 78:

10 (5-Chloro-6-hydroxypyridin-3-yl)-[4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]methanone



15

Similarly as described in example 22 using a solution of 4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 2-hydroxy-3-chloropyridine-5-carboxylic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.


MS (electrospray): m/z: 455 (M+1)

HPLC (method B): R_t = 26.8 min.

25

EXAMPLE 79:

3-(4,5-Dimethylfuran-2-yl)-1-[4-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]propenone



5

Similarly as described in example 22 using a solution of 4-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 3-(4,5-dimethylfuran-2-yl)acrylic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

10


MS (electrospray): m/z: 432 (M+1)

HPLC (method B): R_t = 35.2 min.

15 **EXAMPLE 80:**

(1-Benzyl-1,2,3,4-tetrahydro-isoquinolin-2-yl)-(4-methoxyphenyl)methanone

20




Similarly as described in example 22 using a solution of 1-benzyl-1,2,3,4-tetrahydroisoquinoline in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 4-methoxybenzoic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

HPLC-MS: R_t = 15.0 min. m/z: 358 (M+1)

EXAMPLE 81:

5

(1-Benzyl-1,2,3,4-tetrahydro-isoquinolin-2-yl)-(4-chlorophenyl)methanone




10

Similarly as described in example 22 using a solution of 1-benzyl-1,2,3,4-tetrahydro-isoquinoline in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 4-chlorobenzoic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a 15 suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

HPLC-MS: R_t = 16.1 min. m/z: 362 (M+1)

20 **EXAMPLE 82:**

(1H-Benzimidazol-5-yl)-(1-benzyl-1,2,3,4-tetrahydro-isoquinolin-2-yl)methanone



25


Similarly as described in example 22 using a solution of 1-benzyl-1,2,3,4-tetrahydroisoquinoline in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of benzimidazole-5-carboxylic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in di-
5 chloromethane (1.73 g in 8.3 ml) affords the title compound.

HPLC-MS: R_t = 9.55 min. m/z: 368 (M+1)

EXAMPLE 83:

10

1-(1-Benzyl-1,2,3,4-tetrahydro-isoquinolin-2-yl)-3-furan-3-ylpropenone




15

Similarly as described in example 22 using a solution of 1-benzyl-1,2,3,4-tetrahydroisoquinoline in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 3-(3-furan-3-yl)acrylic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of
20 a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in di-chloromethane (1.73 g in 8.3 ml) affords the title compound.

HPLC-MS: R_t = 14.7 min. m/z: 344 (M+1)

25 **EXAMPLE 84:**

1-(1-Benzyl-1,2,3,4-tetrahydro-isoquinolin-2-yl)-3-(4-methoxyphenyl)propenone




Similarly as described in example 22 using a solution of 1-benzyl-1,2,3,4-tetrahydroisoquinoline in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 4-methoxycinnamic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

HPLC-MS: $R_t = 15.7$ min. m/z: 384 (M+1)

EXAMPLE 85:

1-(1-Benzyl-1,2,3,4-tetrahydro-isoquinolin-2-yl)-3-(4-methoxyphenyl)propan-1-one

15



20 Similarly as described in example 22 using a solution of 1-benzyl-1,2,3,4-tetrahydroisoquinoline in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 4-methoxyhydrocinnamic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.


25

HPLC-MS: $R_t = 15.7$ min. m/z: 386 (M+1)

EXAMPLE 86:

1-(1-Benzyl-1,2,3,4-tetrahydro-isoquinolin-2-yl)-2-(4-methoxyphenyl)ethanone

5




Similarly as described in example 22 using a solution of 1-benzyl-1,2,3,4-tetrahydroisoquinoline in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 4-methoxyphenylacetic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

HPLC-MS: R_t = 15.2 min. m/z: 372 (M+1)

15

Preparation of 4-(4-nitro-phenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine trifluoroacetate:



20 2-(2-Thienyl)-ethylamine (5 g, 39.4 mmol), 4-nitrobenzaldehyde and triethylamine (10 ml) were dissolved in ethanol (100 ml). The reaction mixture was stirred at room temperature for 48 hours. The solid formed was filtered and dried to afford 7.75 g (76%) (4-nitrobenzylidene)-(2-thiophen-2-yl-ethyl)-amine.

25 M.p.: 83.9-84.4 °C.


The above (4-nitrobenzylidene)-(2-thiophen-2-yl-ethyl)-amine (1 g, 3.8 mmol) was added trifluoroacetic acid (100 ml) at once (strongly exothermic reaction). The reaction mixture was stirred at room temperature for 72 hours, then evaporated *in vacuo*. Crystallisation from a mixture of diethyl ether and dichloromethane afforded 1.2 g (85%) of the title compound.

5

M.p.: 128-129.5 °C.

Preparation of dimethyl-[4-(4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-4-yl)-phenyl]-amine:

10



2-(2-Thienyl)-ethylamine (5 g, 39.4 mmol), 4-dimethylaminobenzaldehyde (5.9 g, 94 mmol) triethylamine (6 ml) and ethanol (150ml) were mixed at room temperature. The reaction mixture was stirred at room temperature for 15 hours. The reaction mixture was concen-


15 trated to 75 ml by evaporation *in vacuo* and the solid formed was filtered and dried to afford 6.82 g (67%) *dimethyl-[4-[(2-thiophen-2-yl-ethylimino)-methyl]-phenyl]-amine*.

M.p.: 76.8-77 °C.

20 The above dimethyl-[4-[(2-thiophen-2-yl-ethylimino)-methyl]-phenyl]-amine (1 g, 3.9 mmol) was added TFA (20 mL) at once (strongly exothermic reaction). The reaction mixture was stirred at room temperature for 72 hours, then evaporated *in vacuo*. The crude oil was suspended in dichloromethane (75 ml) and extracted with 1 N hydrochloric acid (50 ml). The aqueous phase was added 2 N sodium hydroxide to pH=10, then extracted with di-
25 chloromethane (3x125 ml). The organic phase was dried with MgSO₄, filtered, evaporated *in vacuo* to afford 0.96 g (95%) of the title compound.

M.p.: 95-98 °C.

30 Preparation of 4-phenyl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine:




2-(2-Thienyl)-ethylamine (2 g, 15.7 mmol) and benzaldehyde (1.67 g, 15.7 mmol) were dissolved in toluene (50 ml) and the reaction mixture was heated at reflux until 20 ml of toluene and water was distilled off in a Dean Stark trap. The remaining mixture was evaporated *in vacuo* to give the crude imine (3.44 g). The crude imine was added trifluoroacetic acid (50 ml) at once (strongly exothermic reaction). The reaction mixture was stirred at room temperature for 72 hours, then evaporated *in vacuo*. The crude oil was dissolved in dichloromethane (50 ml) and washed with 2 N sodium hydroxide (30 ml). The aqueous phase was extracted with dichloromethane (3x30ml). The combined organic phases were dried with MgSO₄, filtered and evaporated *in vacuo*. The residue was purified by column chromatography on silica gel eluting with a mixture of dichloromethane and methanol (19:1). This afforded 0.823 g (24%) of the title compound.

15

M.p.: 79.8-80.7 °C

Preparation of 4-(pyridin-4-yl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine, NNC 60-0372.




20

2-(2-Thienyl)-ethylamine (2 g, 15.7 mmol) 4-pyridylaldehyde (1.68 g, 15.7 mmol), triethylamine (1 ml) and ethanol (15 ml) were mixed and the reaction mixture was stirred at room temperature for 15 hours, then evaporated *in vacuo*. The crude oil was added trifluoroacetic acid (75 ml) at once (strongly exothermic reaction). The reaction mixture was stirred at room temperature for 0.5 hour, then evaporated *in vacuo*. The residue was dissolved in dichloromethane (150 ml) and washed with 2 N sodium hydroxide (100 ml). The aqueous phase was extracted with dichloromethane (3 x 50 ml). The combined organic phases were

dried with MgSO_4 , filtered and evaporated *in vacuo* to give an oil (3.21 g) which was crystallised from a mixture of dichloromethane and hexane to afford 2.4 g (71%) of the title compound.

5 M.p.: 81.8-83.8 °C.

Preparation of 1-(4-trifluoromethoxyphenyl)-1,2,3,4-tetrahydro-isoquinoline:



10

Phenethylamine (0.59 g, 4.9 mmol), 4-trifluoromethoxybenzoic acid (1.0 g, 4.9 mmol) and N-(3-dimethylaminopropyl)-N-ethylcarbodiimide, HCl (1.39 g, 7.3 mmol) were mixed in N,N-dimethylformamide (50 mL) at room temperature and the reaction mixture was stirred for 16 hours. Water (50 mL) was added and the mixture was extracted with ethyl acetate (2 x 50 mL). The combined organic phases were dried (MgSO_4), filtered and evaporated *in vacuo* giving 1.5 g crude product which was purified by column chromatography on silica gel eluting with a mixture of dichloromethane and methanol (9:1). This afforded 0.67 g (45%) of N-phenethyl-4-trifluoromethoxybenzamide.

20 M.p.: 143.2-143.9 °C.

The above N-phenethyl-4-trifluoromethoxybenzamide (0.67 g, 2.2 mmol) was added to a mixture of phosphorous pentoxide (0.92 g, 6.5 mmol) and phosphorous oxychloride (1.03 g, 6.7 mmol) in xylene (50 mL). The reaction mixture was stirred at 140 °C for 16 hours. After 25 cooling, water (50 mL) was added and the mixture was basified with 1 N NaOH. The aqueous phase was extracted with xylene (3 x 50 mL). The combined organic phases were dried (MgSO_4), filtered and evaporated *in vacuo* giving 0.96 g crude product which was purified by column chromatography on silica gel eluting with a mixture of dichloromethane and methanol (9:1). This afforded 0.40 g (62%) of 1-(4-Trifluoromethoxy-phenyl)-3,4-dihydro-isoquinoline 30 as an oil.


The above 1-(4-trifluoromethoxyphenyl)-3,4-dihydro-isoquinoline (0.40 g, 1.4 mmol) was dissolved in methanol (20 mL) and sodium borohydride (0.08 g, 2.1 mmol) was added slowly. The reaction mixture was stirred at room temperature for 2.5 hours. The mixture was evaporated *in vacuo*, redissolved in 1 N NaOH (20 mL) and extracted with dichloromethane (50 mL). The organic phase was dried (MgSO_4), filtered and evaporated *in vacuo*. The remaining oil (0.35 g) was purified by column chromatography on silica gel eluting with a mixture of dichloromethane and methanol (9:1). This afforded 0.56 g (56%) of the title compound.

10 M.p.: 56.6- 57.1 °C.

EXAMPLE 87:

(5-Chlorothiophen-2-yl)-(4-pyridin-4-yl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl)methanone

15



20 Similarly as described in example 22 using a solution of 4-pyridin-4-yl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 5-chlorothiophene-2-carboxylic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

25

HPLC-MS: R_t = 9.27 min. m/z: 361 (M+1)

EXAMPLE 88:

30 (5-Chlorothiophen-2-yl)-[4-(4-dimethylaminophenyl)4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-methanone



5


Similarly as described in example 22 using a solution of 4-dimethylaminophenyl)4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 5-chlorothiophene-2-carboxylic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide 10 hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

HPLC-MS: R_t = 10.70 min. m/z: 403 (M+1)

EXAMPLE 89:

15

(5-Chlorothiophen-2-yl)-[4-(4-nitrophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl)methanone



20

Similarly as described in example 22 using a solution of 4-(4-nitrophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 5-chlorothiophene-2-carboxylic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) 25

and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.


HPLC-MS: R_t = 16.18 min. m/z: 405 (M+1)

5

EXAMPLE 90:

(4-Hydroxymethylphenyl)-(4-phenyl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl)methanone

10




Similarly as described in example 22 using a solution of 4-phenyl-4,5,6,7-tetrahydro-15 thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 4-hydroxymethylbenzoic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

20 HPLC-MS: R_t = 12.33 min. m/z: 350 (M+1)

EXAMPLE 91:

[4-(4-Dimethylaminophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl)-(4-25 hydroxymethylphenyl)-methanone



Similarly as described in example 22 using a solution of 4-(4-dimethylaminophenyl)-4,5,6,7-5 tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 4-hydroxymethylbenzoic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

10 HPLC-MS: R_t = 8.07 min. m/z: 393 (M+1)

EXAMPLE 92:

[4-(4-Nitrophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl)-(4-hydroxymethylphenyl)-15 methanone




Similarly as described in example 22 using a solution of 4-(4-nitrophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 4-hydroxymethylbenzoic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in 25 dichloromethane (1.73 g in 8.3 ml) affords the title compound.

HPLC-MS: R_t = 12.44 min. m/z: 395 (M+1)

EXAMPLE 93:

5 (4-Chlorophenyl)-(4-phenyl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl)methanone



10


Similarly as described in example 22 using a solution of 4-phenyl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 4-chlorobenzoic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in di-15 chloromethane (1.73 g in 8.3 ml) affords the title compound.

HPLC-MS: R_t = 15.90 min. m/z: 355 (M+1)

EXAMPLE 94:

20

(4-Chlorophenyl)-(4-pyridin-4-yl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl)-methanone



25


Similarly as described in example 22 using a solution of 4-pyridin-4-yl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 4-

chlorobenzoic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

5 HPLC-MS: R_t = 9.18 min. m/z: 355 (M+1)

EXAMPLE 95:

(4-Chlorophenyl)-[4-(4-dimethylaminophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl)-
10 methanone



15


Similarly as described in example 22 using a solution of 4-(4-dimethylaminophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 4-chlorobenzoic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

HPLC-MS: R_t = 10.43 min. m/z: 397 (M+1)

EXAMPLE 96:

25

(4-Chlorophenyl)-[4-(4-nitrophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl)-methanone




Similarly as described in example 22 using a solution of 4-(4-nitrophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 4-chlorobenzoic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

10 HPLC-MS: R_t = 15.81 min. m/z: 399 (M+1)

EXAMPLE 97:

(4-Methoxyphenyl)-[4-phenyl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl)-methanone

15




20 Similarly as described in example 22 using a solution of 4-phenyl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 4-methoxybenzoic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

25 HPLC-MS: R_t = 14.83 min. m/z: 350 (M+1)

EXAMPLE 98:

(4-Methoxyphenyl)-(4-pyridin-4-yl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl)-methanone

5




Similarly as described in example 22 using a solution of 4-pyridin-4-yl-4,5,6,7-tetrahydro-
10 thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 4-methoxybenzoic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

15 HPLC-MS: R_t = 8.50 min. m/z: 351 (M+1)

EXAMPLE 99:

[4-(4-Dimethylaminophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(4-methoxyphenyl)-
20 methanone



25


Similarly as described in example 22 using a solution of 4-pyridin-4-yl-4,5,6,7-tetrahydro-
thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 4-

methoxybenzoic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

5 HPLC-MS: R_t = 9.55 min. m/z: 393 (M+1)

EXAMPLE 100:

10 [4-(4-Dimethylaminophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(4-methoxyphenyl)-methanone



15 Similarly as described in example 22 using a solution of 4-(4-nitrophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 4-methoxybenzoic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.


20

HPLC-MS: R_t = 14.80 min. m/z: 395 (M+1)

EXAMPLE 101:

25 3-(4-Methoxyphenyl)-1-(4-phenyl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl)-propenone

100




Similarly as described in example 22 using a solution of 4-phenyl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 4-methoxycinnamic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

10 HPLC-MS: R_t = 15.45 min. m/z: 376 (M+1)

EXAMPLE 102:

(5-Chlorothiophen-2-yl)-(4-phenyl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl)-methanone

15



20 Similarly as described in example 22 using a solution of 4-phenyl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 5-chlorothiophene-2-carboxylic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.


25

HPLC-MS: R_t = 16.42 min. m/z: 360 (M+1)

EXAMPLE 103:

3-(4-Methoxyphenyl)-1-(4-pyridin-4-yl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl)-propenone

5




Similarly as described in example 22 using a solution of 4-pyridin-4-yl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 4-methoxycinnamic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

15 HPLC-MS: R_t = 9.42 min. m/z: 377 (M+1)

EXAMPLE 104:

20 1-[4-(4-Dimethylaminophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-3-(4-methoxyphenyl)-propenone



25

Similarly as described in example 22 using a solution of 4-(4-dimethylaminophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a


solution of 4-methoxycinnamic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

5 HPLC-MS: R_t = 10.32 min. m/z: 418 (M+1)

EXAMPLE 105:

3-(4-Methoxyphenyl)-1-(4-(4-nitrophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl)-

10 propenone



15


Similarly as described in example 22 using a solution of 4-(4-nitrophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 4-methoxycinnamic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

HPLC-MS: R_t = 15.47 min. m/z: 421 (M+1)

EXAMPLE 106:

25

(4-Dimethylaminophenyl)-(4-phenyl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl)-methanone




Similarly as described in example 22 using a solution of 4-phenyl-4,5,6,7-tetrahydro-
 5 thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 4-dimethylaminobenzoic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

10 HPLC-MS: R_t = 11.83 min. m/z: 363 (M+1)

EXAMPLE 107:

(4-Dimethylaminophenyl)-(4-pyridin-4-yl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl)-
 15 methanone




20 Similarly as described in example 22 using a solution of 4-pyridin-4-yl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 4-dimethylaminobenzoic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in
 25 dichloromethane (1.73 g in 8.3 ml) affords the title compound.

HPLC-MS: R_t = 7.5 min. m/z: 364 (M+1)

EXAMPLE 108:

5 (4-Dimethylaminophenyl)-[4-(4-dimethylaminophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-methanone



10

Similarly as described in example 22 using a solution of 4-(4-dimethylaminophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 4-dimethylaminobenzoic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.


HPLC-MS: R_t = 8.15 min. m/z: 406 (M+1)

20 **EXAMPLE 109:**

(4-Dimethylaminophenyl)-[4-(4-nitrophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-methanone

25

105




Similarly as described in example 22 using a solution of 4-(4-nitrophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 4-dimethylaminobenzoic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

10 HPLC-MS: R_t = 12.68 min. m/z: 408 (M+1)

EXAMPLE 110:

(1H-Benzimidazol-5-yl)-(4-phenyl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl)-methanone

15



20 Similarly as described in example 22 using a solution of 4-phenyl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of benzimidazole-5-carboxylic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.


25

HPLC-MS: R_t = 9.27 min. m/z: 360 (M+1)

EXAMPLE 111:

(1H-Benzimidazol-5-yl)-(4-phenyl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl)-methanone

5




10 Similarly as described in example 22 using a solution of 4-(4-dimethylaminophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of benzimidazole-5-carboxylic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

15

HPLC-MS: R_t = 7.17 min. m/z: 403 (M+1)**EXAMPLE 112:**

20 (1H-Benzimidazol-5-yl)-[4-(4-nitrophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-methanone



25


Similarly as described in example 22 using a solution of 4-(4-nitrophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of benzimidazole-5-carboxylic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 5 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

HPLC-MS: R_t = 9.50 min. m/z: 405 (M+1)

10 **EXAMPLE 113:**

(4-Fluorophenyl)-(4-phenyl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl)-methanone

15



Similarly as described in example 22 using a solution of 4-phenyl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 4-fluorobenzoic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a 20 suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

HPLC-MS: R_t = 15.07 min. m/z: 339 (M+1)


25

EXAMPLE 114:

(4-Fluorophenyl)-(4-pyridin-4-yl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl)-methanone

30

108




Similarly as described in example 22 using a solution of 4-pyridin-4-yl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 4-fluorobenzoic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

HPLC-MS: R_t = 8.62 min. m/z: 339 (M+1)

EXAMPLE 115:

[4-(4-Dimethylaminophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(4-fluorophenyl)-methanone




Similarly as described in example 22 using a solution of 4-(4-dimethylaminophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 4-fluorobenzoic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

HPLC-MS: R_t = 9.68 min. m/z: 381 (M+1)

EXAMPLE 116:

(4-Fluorophenyl)-[4-(4-nitrophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-methanone

5




10 Similarly as described in example 22 using a solution of 4-(4-nitrophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 4-fluorobenzoic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

15

HPLC-MS: R_t = 14.95 min. m/z: 383 (M+1)**EXAMPLE 117:**

20 (4-Bromophenyl)-(4-phenyl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl)-methanone



25

Similarly as described in example 22 using a solution of 4-phenyl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 4-


bromobenzoic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

5 HPLC-MS: R_t = 16.07 min. m/z: 398 + 400 (M+1)

EXAMPLE 118:

(4-Bromophenyl)-(4-pyridin-4-yl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl)-methanone

10




15 Similarly as described in example 22 using a solution of 4-pyridin-4-yl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 4-bromobenzoic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

20

HPLC-MS: R_t = 9.30 min. m/z: 399 + 401 (M+1)

EXAMPLE 119:

25 (4-Bromophenyl)-[4-(4-dimethylaminophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-methanone




Similarly as described in example 22 using a solution of 4-(4-dimethylaminophenyl)-4,5,6,7-
 5 tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a
 solution of 4-bromobenzoic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and
 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in
 dichloromethane (1.73 g in 8.3 ml) affords the title compound.

10 HPLC-MS: R_t = 10.72 min. m/z: 441 + 443 (M+1)

EXAMPLE 120:

(4-Bromophenyl)-[4-(4-nitrophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-methanone

15



20 Similarly as described in example 22 using a solution of 4-(4-nitrophenyl)-4,5,6,7-tetrahydro-
 thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 4-
 bromobenzoic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a
 suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in di-
 chloromethane (1.73 g in 8.3 ml) affords the title compound.


25

HPLC-MS: R_t = 15.84 min. m/z: 442 + 444 (M+1)

EXAMPLE 121:

3-Furan-3-yl-1-(4-phenyl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl)-propenone

5




10 Similarly as described in example 22 using a solution of 4-phenyl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 3-furan-3-ylacrylic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

15

HPLC-MS: R_t = 14.77 min. m/z: 336 (M+1)

EXAMPLE 122:

20 3-(3-Furan-3-yl)-1-(4-pyridin-4-yl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl)-propenone



25

Similarly as described in example 22 using a solution of 4-pyridin-4-yl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 3-furan-3-ylacrylic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of

a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.


HPLC-MS: R_t = 8.58 min. m/z: 337 (M+1)

5

EXAMPLE 123:

1-[4-(4-Dimethylaminophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-3-(3-furan-3-yl)-propenone

10




15 Similarly as described in example 22 using a solution of 4-(4-dimethylaminophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 3-furan-3-ylacrylic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

20

HPLC-MS: R_t = 9.38 min. m/z: 379 (M+1)

EXAMPLE 124:

25 3-(3-Furan-3-yl)-1-[4-(4-nitrophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl)-propenone




Similarly as described in example 22 using a solution of 4-(4-nitrophenyl)-4,5,6,7-tetrahydro-
 5 thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 3-furan-3-ylacrylic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

10 HPLC-MS: R_t = 14.57 min. m/z: 381 (M+1)

EXAMPLE 125:

[4-(4-Chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(4-hydroxyphenyl)-
 15 methanone, less polar enantiomer,




20 [4-(4-Chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(4-hydroxyphenyl)-
 methanone (21 mg) was dissolved in a 1:1:1 mixture of ethyl acetate, 2-propanol and n-heptane (3 ml) and fractionated by HPLC using a 21.1 x 250 mm (*R,R*)-Whelk-O column (Regis). The column was eluted isocratically with a mixture of n-heptane and 2-propanol (1:1) at a flow rate of 10 ml/min and fractions were collected corresponding to 1 min/fraction.
 25 The eluting enantiomers were detected spectroscopically by measuring absorbance at a wavelength of 225 nm. Two eluting peaks were detected, corresponding to T_R 24-29 minutes

and T_R 42-50 minutes, respectively. Fractions corresponding to T_R 24-29 minutes were pooled and evaporated to yield 8.8 mg of the title compound.

100% ee (Determined by HPLC using a 4.6 x 250 mm (*R,R*)-Whelk-O column eluted with n-
5 heptane:2-propanol (1:1), the flow rate was 1 ml/min, eluting sample was monitored spectro-
scopically at 225 and 280 nm, T_R 8.9 min).

EXAMPLE 126:

10 [4-(4-Chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(4-hydroxyphenyl)-
methanone, more polar enantiomer,



15

Fractions from example 125 corresponding to T_R 42-50 minutes were pooled and evaporated to yield 9.1 mg of the title compound.


99.4 % ee (Conditions as described in example 125, T_R 12.5 min).

20

EXAMPLE 127:

(1H-Benzimidazol-5-yl)-[4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]methanone, less polar enantiomer,

25




(1H-Benzimidazol-5-yl)-[4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]methanone (15 mg) was dissolved in a 1:1 mixture of n-heptane:2-propanol (2 ml) and fractionated by HPLC using a 20 x 250 mm Chiralpak AS column. The column was eluted isocratically with a mixture of n-heptane, ethanol and diethylamine (70:30:0.1) at a flow rate of 6 ml/min and fractions collected corresponding to 1 min/fraction. The eluting enantiomers were detected spectroscopically by measuring absorbance at a wavelength of 225 nm. Two eluting peaks were detected, corresponding to T_R 16-19 minutes and T_R 27-35 minutes, respectively. Fractions corresponding to T_R 16-19 minutes were pooled and evaporated to yield 7.2 mg of the title compound.

100% ee (Determined by HPLC using a 4.6 x 250 mm Chiralpak AS column eluted with a mixture of n-heptane, ethanol and diethylamine (70:30:0.07), the flow rate was 0.6 ml/min, 15 eluting sample was monitored spectroscopically at 225 and 245 nm, T_R 8.4 min).

EXAMPLE 128:

20 (1H-Benzimidazol-5-yl)-[4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]methanone, more polar enantiomer,




25 Fractions from example 127 corresponding to T_R 27-35 minutes were pooled and evaporated to yield 8.0 mg of the title compound.

>99% ee (Conditions as described in example 127, T_R 14.7 min).

EXAMPLE 129:

5 (5-Chlorothiophen-2-yl)-[1-(4-trifluoromethoxyphenyl)-1,2,3,4-tetrahydroisoquinolin-2-yl]-methanone



10

Similarly as described in example 22 using a solution of 1-(4-trifluoromethoxyphenyl)-1,2,3,4-tetrahydroisoquinoline in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 5-chlorothiophene-2-carboxylic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.


15

HPLC-MS: $R_t = 17.75$ min. m/z: 438 (M+1)

EXAMPLE 130:

20

(4-Chlorophenyl)-[1-(4-trifluoromethoxyphenyl)-1,2,3,4-tetrahydroisoquinolin-2-yl]-methanone




25

Similarly as described in example 22 using a solution of 1-(4-trifluoromethoxyphenyl)-1,2,3,4-tetrahydroisoquinoline in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 4-chlorobenzoic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of 5 a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

HPLC-MS: R_t = 17.42 min. m/z: 432 (M+1)

10 **EXAMPLE 131:**

(4-Methoxyphenyl)-[1-(4-trifluoromethoxyphenyl)-1,2,3,4-tetrahydroisoquinolin-2-yl]-methanone



15


Similarly as described in example 22 using a solution of 1-(4-trifluoromethoxyphenyl)-1,2,3,4-tetrahydroisoquinoline in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 4-methoxybenzoic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml 20 of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

HPLC-MS: R_t = 16.42 min. m/z: 428 (M+1)

25 **EXAMPLE 132:**

3-(4-Methoxyphenyl)-1-[1-(4-trifluoromethoxyphenyl)-1,2,3,4-tetrahydroisoquinolin-2-yl]propanone

119




Similarly as described in example 22 using a solution of 1-(4-trifluoromethoxyphenyl)-1,2,3,4-tetrahydroisoquinoline in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 4-methoxycinnamic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

HPLC-MS: $R_t = 17.02$ min. m/z: 454 (M+1)

EXAMPLE 133:

3-Furan-3-yl-1-[1-(4-trifluoromethoxyphenyl)-1,2,3,4-tetrahydroisoquinolin-2-yl]propenone



15

Similarly as described in example 22 using a solution of 1-(4-trifluoromethoxyphenyl)-1,2,3,4-tetrahydroisoquinoline in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 3-furan-3-ylacrylic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.


HPLC-MS: $R_t = 16.12$ min. m/z: 414 (M+1)

25

EXAMPLE 134:

(4-Trifluoromethoxyphenyl)-[4-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]methanone

5




Similarly as described in example 22 using a solution of 4-(4-trifluoromethylphenyl)-4,5,6,7-
10 tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a
solution of 4-trifluoromethoxybenzoic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15
mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hy-
drochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

15 HPLC-MS: R_t = 17.01 min. m/z: 472 (M+1)

EXAMPLE 135:

(7-Methoxybenzofuran-2-yl)-[4-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]methanone




Similarly as described in example 22 using a solution of 4-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 7-methoxybenzofuran-2-carboxylic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

HPLC-MS: R_t = 16.98 min. m/z: 458 (M+1)

10

EXAMPLE 136:

Benzofuran-2-yl-[4-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]methanone



15


Similarly as described in example 22 using a solution of 4-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of benzofuran-2-carboxylic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

HPLC-MS: R_t = 17.01 min. m/z: 428 (M+1)

25

EXAMPLE 137:

3-(4-Fluorophenyl)-1-[4-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]propanone




Similarly as described in example 22 using a solution of 4-(4-trifluoromethylphenyl)-4,5,6,7-
 5 tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a
 solution of 4-fluorocinnamic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol)
 and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

10 HPLC-MS: R_t = 16.58 min. m/z: 432 (M+1)

EXAMPLE 138:

15 3-(4-Trifluoromethylphenyl)-1-[4-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]propenone




Similarly as described in example 22 using a solution of 4-(4-trifluoromethylphenyl)-4,5,6,7-
 20 tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a
 solution of 4-trifluoromethylcinnamic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15
 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hy-
 drochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

25 HPLC-MS: R_t = 17.38 min. m/z: 482 (M+1)

EXAMPLE 139:

5 3-(3-Methoxyphenyl)-1-[4-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]propenone




10 Similarly as described in example 22 using a solution of 4-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 3-methoxycinnamic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

15 HPLC-MS: R_t = 16.54 min. m/z: 444 (M+1)

EXAMPLE 140:

20 3-(4-Chlorophenyl)-1-[4-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]propenone



25 Similarly as described in example 22 using a solution of 4-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 4-chlorocinnamic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol)


and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

HPLC-MS: $R_t = 17.41$ min. m/z: 448 (M+1)

5

EXAMPLE 141:

3-(4-Methoxyphenyl)-1-[4-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]propan-1-one



10


Similarly as described in example 22 using a solution of 4-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a solution of 4-methoxyhydrocinnamic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

HPLC-MS: $R_t = 16.41$ min. m/z: 446 (M+1)

20

EXAMPLE 142:

3-(4-Chlorophenyl)-1-[4-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]propan-1-one



25

Similarly as described in example 22 using a solution of 4-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol), a 5 solution of 4-chlorohydrocinnamic acid in N,N-dimethylformamide (0.375 M, 0.4 ml, 0.15 mmol) and 0.25 ml of a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride in dichloromethane (1.73 g in 8.3 ml) affords the title compound.

HPLC-MS: R_t = 17.38 min. m/z: 450 (M+1)

10

General:

The HPLC-MS analyses were performed on a PE Sciex API 100 LC/MS System using a WatersTM 3 mm x 150 mm 3.5 μ C-18 Symmetry column and positive ionspray with a flow 15 rate at 20 μ L/minute. The column was eluted with a linear gradient of 5-90% A, 85-0% B and 10% C in 15 minutes at a flow rate of 1 ml/min (solvent A = acetonitrile, solvent B = water and solvent C = 0.1% trifluoroacetic acid in water).


The given HPLC (method B) refers to the following system:

20

The used HPLC-system was comprised of a Merck Hitachi L-4000 UV Detector (detection at 254 nm), a Merck Hitachi L-6200A Intelligent Pump, a Merck Hitachi AS-2000A Autosampler, and a 4 mm * 250 mm 5 μ Licosorp RP-18 column. The compounds were eluted using a gradient of 20% to 80% acetonitrile/0.1% trifluoroacetic acid/water during 30 minutes at 1 25 ml/minute, followed by a gradient of 80% to 100% acetonitrile/0.1% trifluoroacetic acid/water during 5 minutes at 1 ml/minute then with 100% acetonitrile/0.1% trifluoroacetic acid during 1 minute at 1 ml/minute and 4 minutes at 2 ml/minute.

CLAIMS

1. A compound of the general formula I



5

wherein

A together with the double bond of formula I forms a cyclic system selected from the group consisting of benzene, thiophene, furan, pyridine, pyrimidine, pyrazine, pyridazine, pyrrole, indole, pyrazole, imidazole, oxazole, isoxazole or thiazole,

10

R¹ is an optionally substituted C₁₋₆-alkyl, or optionally substituted aryl,

R² is an optionally substituted C₁₋₆-alkyl, optionally substituted aralkyl, or COR³,

15

R³ is an optionally substituted C₁₋₆-alkyl, optionally substituted aralkyl, or optionally substituted aryl,

20

R⁴ and R⁵ independently are hydrogen, halogen, perhalomethyl, optionally substituted C₁₋₆-alkyl, hydroxy, optionally substituted C₁₋₆-alkoxy, nitro, cyano, amino, optionally substituted mono- or optionally substituted di-C₁₋₆-alkylamino, acylamino, C₁₋₆-alkoxycarbonyl, carboxy or carbamoyl,

n is 0, 1, or 2, and

m is 0, 1, or 2,

25

or a salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric form.

2. A compound according to claim 1, wherein A is selected from benzene or thiophene.

3. A compound according to any one of claims 1 and 2, wherein R¹ is optionally substituted phenyl.
4. A compound according to any one of the preceding claims, wherein each one of R¹, R²,
5 and R³ is substituted with one or more substituents.
5. A compound according to claim 3 or 4, wherein the substituents of R¹ is halogen, perhalomethyl, perhalomethoxy, or C₁₋₆-alkoxy.
- 10 6. A compound according to claim 3 or 4, wherein the substituents of R¹ are selected from the group consisting of hydrogen, halogen, perhalomethyl, perhalomethoxy, or C₁₋₆-alkoxy.
- 15 7. A compound according to claim 5 or 6, wherein the substituents of R¹ are selected from the group consisting of chloro, trifluoromethyl, methoxy, trifluoromethoxy.
8. A compound according to claim 3, wherein R¹ is selected from the group consisting of phenyl, 4-chlorophenyl, 4-trifluoromethylphenyl, and 4-trifluoromethoxyphenyl.
- 20 9. A compound according to any one of claims 1 to 3, wherein R¹ is 2,3-dihydrobenzofuran or 4-methoxyphenyl.
10. A compound according to any one of the preceding claims wherein R² is COR³ or
25 (CH₂)_q-aryl, and q is 0, 1, 2, 3, 4, 5, or 6.
11. A compound according to claim 10, wherein R³ is selected from the group consisting of phenyl, 3-methoxyphenyl, 4-methoxyphenyl, 4-chlorophenyl, 4-trifluoromethylphenyl, 4-(2-dimethylaminoethoxy)phenyl, or 4-(2-morpholin-4-ylethoxy)phenyl.
- 30 12. A compound according to claim 10, wherein R³ is selected from the group consisting of 4-methylphenyl, 3,4-dimethoxyphenyl, 4-ethoxyphenyl, 4-fluorophenyl, 4-trifluoromethylphenyl, dimethylaminophenyl, 4-(2-carboxyethenyl)phenyl, 4-(2-dimethylaminoethoxy)phenyl, 4-(2-morpholin-4-ylethoxy)phenyl, 1H-indol-5-yl, 3-chloro-

4-methoxyphenyl, and 1H-benzimidazol-5-yl.

13. A compound according to any one of the preceding claims, wherein R⁴ and R⁵ independently is hydrogen, chloro, or methoxy.


5

14. A compound according to any one of the preceding claims, wherein n is 0 or 1 and m is 0 or 1.

15. A compound according to any one of the preceding claims, wherein n is 0 and m is 0 or 1.

10

16. A compound according to claim 1 and having the general formula Ia:




(Ia)

wherein R⁷ is hydrogen, halogen, preferably chloro, methoxy, perhalomethoxy, preferably trifluoromethoxy, perhalomethyl, preferably trifluoromethyl, diloweralkylamino, preferably dimethylamino, or nitro,

and R⁶ and R⁸ independently are hydrogen, hydroxy, halogen, preferably chloro, bromo or fluoro, methyl, tert-butyl, phenyl, dimethylamino, methoxy, ethoxy, 2-dimethylaminoethoxy, 2-carboxyethenyl, 2-morpholin-4-ylethoxy, perhalomethyl, preferably trifluoromethyl, perhalomethoxy, preferably trifluoromethoxy, carboxy, cyano, methylthio, methylsulfonyl, acetamido, nitro, acetyl, acetoxy, or hydroxymethyl.

20

17. A compound according to claim 1 and having the general formula (Ia):



(Ia)

wherein R⁷ is halogen, perhalomethyl, or perhalomethoxy

and R⁶ and R⁸ independently are hydrogen, methoxy, ethoxy, hydroxy, fluoro, chloro, bromo, iodo, methyl, trifluoromethyl, dimethylamino, 2-carboxyethenyl, 2-

dimethylaminoethoxy, or 2-morpholin-4-ylethoxy.

18. A compound according to claim 16, wherein R⁷ is selected from the group consisting of chloro, methoxy and trifluoromethyl.

5


19. A compound according to claim 16 or 17 wherein R⁷ is trifluoromethoxy.

10 20. A compound according to any one of claims 17, 18 and 19, wherein R⁶ and R⁸ inde-

pendently are hydrogen, methoxy, chloro, trifluoromethyl, 2-dimethylaminoethoxy, or 2-

morpholin-4-ylethoxy.


21. A compound according to claim 1 and having the general formula (Ib):



15 wherein R⁷ is as described above, and

R⁶ is hydroxy, halogen, preferably chloro or fluoro, methyl, dimethylamino, methoxy, ethoxy, perhalomethyl, preferably trifluoromethyl, perhalomethoxy, preferably trifluoromethoxy, cyano, methylthio, acetyl, acetoxy, or hydroxymethyl.


20 22. A compound according to claim 1 and having the general formula (Ic):



wherein R⁷ is as defined above, and

R⁹ is 4-pyridyl, 5-hydroxypyrazin-2-yl, 5-chloro-6-hydroxypyridin-3-yl, 2-chloropyridin-3-yl, benzofuran-2-yl, benzothiophen-2-yl-, 7-methoxybenzofuran-2-yl, indolyl, preferably 1H-indol-5-yl, benzimidazol, preferably 1H-benzimidazol-5-yl or thienyl, preferably 5-chlorothiophen-2-yl.

23. A compound according to claim 1 and having the general formula (Ic):




wherein R⁷ is as defined above and R⁹ is indolyl, preferably 1H-indol-5-yl or benzimidazol, preferably 1H-benzimidazol-5-yl.

5

24. A compound according to claim 22 wherein R⁷ is as defined above and R⁹ is benzothiophen-2-yl, indolyl, preferably 1H-indol-5-yl, or benzimidazol, preferably 1H-benzimidazol-5-yl.

10


25. A compound according to claim 1 and having the general formula (Id):



wherein R⁷ is as defined above, and R¹⁰ is optionally substituted aralkyl as defined above, preferably 2-(4-methoxyphenyl)-ethenyl, 2-(3-methoxyphenyl)-ethenyl, 2-(4-chlorophenyl)-ethenyl, 2-(4-fluorophenyl)-ethenyl, 2-(4-trifluoromethylphenyl)-ethenyl, 2-(4-methoxyphenyl)-ethyl, 2-(4-chlorophenyl)-ethyl, 4-chlorobenzyl, 4-methoxybenzyl, 2-(2-furyl)-ethenyl, 2-(4,5-dimethyl-2-furyl)-ethenyl, 2-(5-methyl-2-furyl)-ethenyl, 2-(3-furyl)-ethenyl, 2-(2-thienyl)-ethenyl, or 2-(3-thienyl)-ethenyl.

15

20 26. A compound according to claim 1 and having the general formula (Id):




wherein R⁷ is as defined above, and R¹⁰ is 4-methoxyphenyl-2-ethenyl.

27. A compound according to claim 25 wherein R⁷ is as defined above and R¹⁰ is optionally substituted aralkyl as defined above, preferably 2-(4-methoxyphenyl)-ethenyl, 2-(2-furyl)-ethenyl, 2-(5-methyl-2-furyl)-ethenyl, 2-(3-furyl)-ethenyl, or 2-(3-thienyl)-ethenyl.

5

28. A compound according to claim 1 and having the formula (Ie):




wherein R¹¹ is pyridyl, preferably 4-pyridyl, and

10

R⁶ and R⁸ independently are hydrogen, hydroxy, halogen, preferably chloro, bromo or fluoro, methyl, tert-butyl, phenyl, dimethylamino, methoxy, ethoxy, 2-dimethylaminoethoxy, 2-carboxyethenyl, 2-morpholin-4-ylethoxy, perhalomethyl, preferably trifluoromethyl, perhalomethoxy, preferably trifluoromethoxy, carboxy, cyano, methylthio, methysulfonyl, acetamido, nitro, acetyl, acetoxy, or hydroxymethyl.

15

29. A compound according to claim 1 and having the formula (If):




20

wherein R¹⁰ is optionally substituted aralkyl as defined above, preferably 2-(4-methoxyphenyl)-ethenyl, 2-(3-methoxyphenyl)-ethenyl, 2-(4-chlorophenyl)-ethenyl, 2-(4-fluorophenyl)-ethenyl, 2-(4-trifluoromethylphenyl)-ethenyl, 2-(4-methoxyphenyl)-ethyl, 2-(4-chlorophenyl)-ethyl, 4-chlorobenzyl, 4-methoxybenzyl, 2-(2-furyl)-ethenyl, 2-(4,5-dimethyl-2-furyl)-ethenyl, 2-(5-methyl-2-furyl)-ethenyl, 2-(3-furyl)-ethenyl, 2-(2-thienyl)-ethenyl, or 2-(3-thienyl)-ethenyl, and

R¹¹ is pyridyl, preferably 4-pyridyl.

30 30. A compound according to claim 1 and having the formula (Ig):




wherein R¹² is aryl or aralkyl, and

5

R⁶ and R⁸ independently are hydrogen, hydroxy, halogen, preferably chloro, bromo or fluoro, methyl, tert-butyl, phenyl, dimethylamino, methoxy, ethoxy, 2-dimethylaminoethoxy, 2-carboxyethenyl, 2-morpholin-4-ylethoxy, perhalomethyl, preferably trifluoromethyl, perhalomethoxy, preferably trifluoromethoxy, carboxy, cyano, methylthio, methylsulfonyl, acetamido, nitro, acetyl, acetoxy, or hydroxymethyl.

10

31. A compound according to claim 1 and having the formula (lh):



15

wherein R¹² is aryl, preferably 4-trifluoromethoxyphenyl, or aralkyl, preferably benzyl, and

20 R¹³ is aralkyl as defined above, preferably 2-(4-methoxyphenyl)-ethenyl, 2-(3-methoxyphenyl)-ethenyl, 2-(4-chlorophenyl)-ethenyl, 2-(4-fluorophenyl)-ethenyl, 2-(4-trifluoromethylphenyl)-ethenyl, 2-(4-methoxyphenyl)-ethyl, 2-(4-chlorophenyl)-ethyl, 4-chlorobenzyl, 4-methoxybenzyl, 2-(2-furyl)-ethenyl, 2-(4,5-dimethyl-2-furyl)-ethenyl, 2-(5-methyl-2-furyl)-ethenyl, 2-(3-furyl)-ethenyl, 2-(2-thienyl)-ethenyl, or 2-(3-thienyl)-ethenyl.

25

32. A compound according to claim 1, selected from the group consisting of

(+)-[4-(4-Chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(4-methoxyphenyl)-methanone, (compound No. 1),

(-)-[4-(4-Chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(4-methoxyphenyl)-methanone, (compound No. 2),

(+)-[4-(4-Methoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(4-trifluoromethylphenyl)-methanone, (compound No. 3),

5 (-)-[4-(4-Methoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(4-trifluoromethylphenyl)-methanone, (compound No. 4),

[4-(4-Trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(4-methoxyphenyl)-methanone, (compound No. 5),

(+)-[4-(4-Trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(4-methoxyphenyl)-methanone, (compound No. 6),

10 (-)-[4-(4-Trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(4-methoxyphenyl)-methanone, (compound No. 7),

[4-(4-Trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(3-methoxyphenyl)-methanone, (compound No. 8),

15 (+)-[4-(4-Trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(3-methoxyphenyl)-methanone, (compound No. 9),

(-)-[4-(4-Trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(3-methoxyphenyl)-methanone, (compound No. 10),

[4-(4-Chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-phenyl-methanone,

20 (compound No. 11),

(+)-[4-(4-Chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-phenyl-methanone, (compound No. 12),

(-)-[4-(4-Chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-phenyl-methanone, (compound No. 13),

25 (4-(2-Dimethylaminoethoxy)phenyl)-[4-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-methanone, (compound No. 14),

(+)-(4-(2-Dimethylaminoethoxy)phenyl)-[4-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-methanone, (compound No. 15),

(-)-(4-(2-Dimethylaminoethoxy)phenyl)-[4-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-methanone, (compound No. 16),

30 [4-(4-Chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(4-(2-[2-morpholin-4-ylethoxy)phenyl]-methanone, (compound No. 17),

(+)-[4-(4-Chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(4-(2-[2-morpholin-4-ylethoxy)phenyl]-methanone, (compound No. 18),

(-)-[4-(4-Chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(4-(2-morpholin-4-ylethoxy)phenyl)-methanone, (compound No. 19),
[4-(4-Trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(4-dimethylaminophenyl)-methanone, (compound No 20),
5 3-{4-[4-(4-Chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine-5-carbonyl]phenyl}-acrylic acid, (compound No 21),
(4-Chlorophenyl)-[4-(4-chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-methanone, both the racemate, the two pure enantiomers, and mixtures thereof (compound No 22),
10 [4-(4-Trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(4-methoxyphenyl)-methanone, (compound No. 24),
[4-(4-Trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(4-methoxyphenyl)-methanone, (compound No. 25),
[4-(2-Dimethylaminoethoxy)-phenyl]-[4-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-methanone, (compound No. 26),
15 [4-(2-Dimethylaminoethoxy)-phenyl]-[4-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-methanone, (compound No. 27),
[4-(4-Chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-[4-(2-morpholin-4-ylethoxy)phenyl]-methanone, (compound No. 28),
20 [4-(4-Chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-[4-(2-morpholin-4-ylethoxy)phenyl]-methanone, (compound No. 29),
[4-(4-Trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(4-methoxyphenyl)-methanone, (compound No. 30),
25 [4-(4-Trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(4-methoxyphenyl)-methanone, (compound No. 31),
[4-(4-Trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(4-methoxyphenyl)-methanone, (compound No. 32),
[4-(4-Chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(1H-indol-5-yl)-methanone, (compound No. 33),
30 (1H-Indol-5-yl)-[4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-methanone, (compound No. 34),
[4-(4-Chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(4-fluorophenyl)-methanone, (compound No. 35),
[4-(4-Trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(4-

fluorophenyl)-methanone, (compound No. 36),
4-(4-Chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-[4-(2-dimethylaminoethoxy)phenyl]-methanone, (compound No. 37),
[4-(2-Dimethylaminoethoxy)phenyl]-[4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-methanone, (compound No. 38),
5 [7-Chloro-1-(2,3-dihydrobenzofuran-7-yl)-8-methoxy-1,2,4,5-tetrahydrobenzo[d]azepin-3-yl]-[4-(2-dimethylaminoethoxy)-phenyl]-methanone, (compound No. 39),
[4-(3,4-Dimethoxyphenyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridin-6-yl]-[4-(2-dimethylaminoethoxy)-phenyl]-methanone, (compound No. 40),
10 (3,4-Dimethoxyphenyl)-[4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]methanone, (compound No. 41),
(3-Chloro-4-methoxyphenyl)-[4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]methanone, (compound No. 42),
15 (4-Ethoxyphenyl)-[4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]methanone, (compound No. 43),
(4-Methylphenyl)-[4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]methanone, (compound No. 44),
3-(4-Methoxyphenyl)-1-[4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]propenone, (compound No. 45),
20 (1H-Benzimidazol-5-yl)-[4-(4-trifluoromethoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]methanone, (compound No. 46),
or a salt thereof with a pharmaceutically acceptable acid or base.

33. A salt of a compound according to the preceding claim with a pharmaceutically acceptable base.

25
34. A pharmaceutical composition comprising, as an active ingredient, a compound according to any one of claims 1 - 33, or a pharmaceutical acceptable salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric form together with one or more pharmaceutically acceptable carriers or diluents.

30
35. A pharmaceutical composition for use in the treatment of diseases of the endocrinological system such as hyperglycaemia and diabetes comprising, as an active ingredient, a

compound according to any of the claims 1 - 33 or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric form together with one or more pharmaceutically acceptable carriers or diluents.

5

36. The pharmaceutical composition according to claim 34 or 35 in the form of an oral dosage unit or a parenteral dosage unit.

10

37. A pharmaceutical composition according to claim 34 or 35 wherein said ingredient is present in a unit dose in a range from about 0.05 to 1000, preferably from about 0.1 to 500 and especially in the range from 5 to 200 mg.

15

38. A compound according to any of the claims 1 - 33 or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric form for therapeutical use.

20

39. A compound according to any of the claims 1 - 33 or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric form for therapeutical use in the treatment or prevention of diseases of the endocrinological system, preferably hyperglycaemia or diabetes.

25

40. A compound according to any of the claims 1 - 33 or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric form, characterized by having a glucose-6-phosphatase inhibitory activity corresponding to an IC_{50} value of less than 100 μ M, preferably less than 10 μ M, more preferably less than 1 μ M, still more preferably less than 100 nM.

30

41. The use of a compound according to any of the claims 1 - 33 or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric form

for the preparation of a medicament.

42. The use of a compound according to any of the claims 1 - 33 or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric form for the preparation of a medicament for the treatment or prevention of diseases of the endocrinological system, preferably hyperglycaemia or diabetes.

5

43. The use of a compound according to any of the claims 1 - 33 or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric form for the preparation of a medicament for the treatment or prevention of glycogen storage disease or hypoglycaemia.

10

15 44. The use of a compound selected from the group consisting of [4-(4-Chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(4-methoxyphenyl)-methanone, (compound No. 47),
(4-Chlorophenyl)-[4-(4-chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-methanone, (compound No. 48),
20 (4-Chlorophenyl)-[4-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-methanone, (compound No. 49),
(2-Chlorophenyl)-[4-(4-methoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-methanone, (compound No. 50),
25 (4-Chlorophenyl)-[4-(methoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-methanone, (compound No. 51),
[4-(4-Methoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(4-trifluoromethylphenyl)-methanone, (compound No. 52),
30 (2-Chloropyridin-3-yl)-[4-(4-methoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-methanone, (compound No. 53),
[4-(4-Chlorophenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(2-thienyl)-methanone, (compound No. 54),
[4-(4-Methoxyphenyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-(2-thienyl)-methanone, (compound No. 55),
35 (4-Chlorophenyl)-(4-propyl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl)-methanone,

(compound No. 56).

or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric form for the preparation of a medicament.

5 45. The use of a compound selected from the group of compounds of the preceding claim for the preparation of a medicament for the treatment or prevention of diseases of the endocrinological system.

10

46. The use of a compound selected from the group of compounds of claim 44 for the preparation of a medicament for the prevention or treatment of hyperglycaemia or diabetes, preferably NIDDM.

15 47. A method for the treatment of ailments in a subject in need thereof comprising administering an effective amount of a compound according to any one of claims 1-33, and 44, or of a composition according to any one of the preceding composition claims, to said subject.

20 48. A method of treating or preventing diseases of the endocrinological system, preferably hyperglycaemia or diabetes in a subject in need thereof comprising administering an effective amount of a compound according to any one of the preceding compound claims to said subject.

25 49. A method of treating or preventing hyperglycaemia or hypoglycaemia in a subject in need thereof comprising administering an effective normoglycaemic amount of a pharmaceutically acceptable salt of a compound according to any one of the preceding compound claims, or of a composition according to any one of the preceding composition claims, to said subject.

30

50. A process for the manufacture of a medicament, particular to be used in the treatment or prevention of diseases of the endocrinological system, such as, hyperglycaemia, diabetes, hypoglycaemia, and glycogen storage disease, which process comprises bringing a compound according to any of the claims 1-33, and 44 or a pharmaceutically accept-

able salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric form thereof, into a galenic dosage form.

5 51. Any novel feature or combination of features as described herein.

INTERNATIONAL SEARCH REPORT

1

International application No.

PCT/DK 98/00083

A. CLASSIFICATION OF SUBJECT MATTER

IPC6: C07D 495/04, C07D 217/06, A61K 31/435, A61K 31/47

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE, DK, FI, NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CA, WPI

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 9634870 A1 (SYNTHELABO), 7 November 1996 (07.11.96) --	1-46, 50-51
X	WO 8705295 A1 (UNIVERSITE LOUIS PASTEUR), 11 Sept 1987 (11.09.87) --	1-46, 50-51
X	EP 0088250 A2 (BOEHRINGER INGELHEIM KG), 14 Sept 1983 (14.09.83), see claims 1, 2 --	1-3, 6-8, 13, 14-15, 51
X	US 4681888 A (ANDRE ESANU), 21 July 1987 (21.07.87), see claim 1 --	1-3, 5-7, 13, 14-15, 51

 Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

12 June 1998

26-06-1998

Name and mailing address of the ISA/
Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. + 46 8 666 02 86

Authorized officer

Eva Johansson
Telephone No. + 46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 98/00083

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0157324 A2 (BAYER AG), 9 October 1985 (09.10.85) -- -----	35-46,50

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 98/00083

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.: 1-15, 51 because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

Claims 1-15 and 51 are too broadly formulated and do not comply with Art. 6. PCT prescribing that claims shall be clear and concise.
For this reason the search has been limited to claims 16-32 and 44.
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.



No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.
PCT/DK 98/00083

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9634870 A1	07/11/96	AU 5652096 A		21/11/96
		EP 0823912 A		18/02/98
		FR 2733750 A,B		08/11/96
		IL 118119 D		00/00/00
		NO 975020 A		05/01/98
WO 8705295 A1	11/09/87	EP 0236251 A		09/09/87
		FR 2595356 A,B		11/09/87
		JP 63502750 T		13/10/88
		US 4925943 A		15/05/90
EP 0088250 A2	14/09/83	SE 0088250 T3		
		AU 554783 B		04/09/86
		CA 1197506 A		03/12/85
		CS 237337 B		16/07/85
		CS 237341 B		16/07/85
		CS 237342 B		16/07/85
		CS 8301370 A		14/12/84
		CS 8305720 A		14/12/84
		CS 8305721 A		14/12/84
		DE 3207939 A		15/09/83
		DK 87383 A		06/09/83
		FI 74282 B,C		30/09/87
		FI 830661 A		06/09/83
		GB 2117762 A,B		19/10/83
		JP 58162591 A		27/09/83
		PT 76335 B		03/02/86
		SU 1187723 A		23/10/85
		US 4482559 A		13/11/84
		US 4550106 A		29/10/85
US 4681888 A	21/07/87	AR 241021 A		30/04/91
		AT 394559 B		11/05/92
		BE 903499 A		22/04/86
		CA 1292233 A		19/11/91
		CH 665211 A,B		29/04/88
		DE 3540529 A,C		22/05/86
		DK 158738 B,C		09/07/90
		DK 527685 A		17/05/86
		FI 81352 B		29/06/90
		FI 854298 A		17/05/86
		FR 2573309 A,B		23/05/86
		FR 2573429 A,B		23/05/86
		GB 2167065 A,B		21/05/86
		HK 10389 A		10/02/89
		IE 58591 B		20/10/93
		JP 1878126 C		07/10/94
		JP 61122288 A		10/06/86
		LU 86137 A		24/03/86
		NL 8502946 A		16/06/86
		OA 8172 A		31/03/87
		PT 81487 B		30/12/87
		SE 453505 B,C		08/02/88
		SE 8505369 A		17/05/86

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.
PCT/DK 98/00083

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0157324 A2	09/10/85	SE 0157324 T3	
		AU 569787 B	18/02/88
		AU 4083485 A	10/10/85
		CA 1255660 A	13/06/89
		DE 3412947 A	17/10/85
		DE 3564684 A	06/10/88
		DK 154385 A	07/10/85
		DK 163831 B	06/04/92
		JP 1908465 C	24/02/95
		JP 6033276 B	02/05/94
		JP 60228485 A	13/11/85
		US 4642310 A	10/02/87